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Severe malaria has a high mortality rate (15–20%) despite treatment with
effective antimalarial drugs. Adjunctive therapies for severe malaria that target
the underlying disease process are therefore urgently required. Adhesion of
erythrocytes infected with Plasmodium falciparum to human cells has a key
role in the pathogenesis of life-threatening malaria and could be targeted with
antiadhesion therapy. Parasite adhesion interactions include binding to
endothelial cells (cytoadherence), rosetting with uninfected erythrocytes and
platelet-mediated clumping of infected erythrocytes. Recent research has
started to define the molecular mechanisms of parasite adhesion, and
antiadhesion therapies are being explored. However, many fundamental
questions regarding the role of parasite adhesion in severe malaria remain
unanswered. There is strong evidence that rosetting contributes to severe
malaria in sub-Saharan Africa; however, the identity of other parasite adhesion
phenotypes that are implicated in disease pathogenesis remains unclear. In
addition, the possibility of geographic variation in adhesion phenotypes
causing severe malaria, linked to differences in malaria transmission levels
and host immunity, has been neglected. Further research is needed to realise
the untapped potential of antiadhesion adjunctive therapies, which could
revolutionise the treatment of severe malaria and reduce the high mortality
rate of the disease.
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Plasmodium falciparum is the causative agent of
human falciparum malaria and is responsible
for a huge burden of global mortality and
morbidity (Ref. 1). The parasite has a complex
life cycle involving both human and mosquito
hosts (Fig. 1), and despite more than a century
of research, has proven recalcitrant to control
and eradication measures. The clinical features
of malaria occur during the blood stage of
infection, when the parasite grows and
Life cycle of Plasmodium falciparum
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Figure 1. Life cycle of Plasmodium falciparum. When an infected female Anopheles mosquito takes a blood
meal, sporozoite forms of P. falciparum are injected into the human skin. The sporozoites migrate into the
bloodstream and then invade liver cells. The parasite grows and divides within liver cells for 8–10 days, then
daughter cells called merozoites are released from the liver into the bloodstream, where they rapidly invade
erythrocytes. Merozoites subsequently develop into ring-stage, pigmented-trophozoite-stage and schizont-
stage parasites within the infected erythrocyte. P. falciparum-infected erythrocytes express parasite-derived
adhesion molecules on their surface, resulting in sequestration of pigmented-trophozoite and schizont
stages in the microvasculature. The asexual intraerythrocytic cycle lasts for 48 hours, and is completed by
the formation and release of new merozoites that will re-invade uninfected erythrocytes. It is during this
asexual bloodstream cycle that the clinical symptoms of malaria (fever, chills, impaired consciousness, etc.)
occur. During the asexual cycle, some of the parasite cells develop into male and female sexual stages
called gametocytes that are taken up by feeding female mosquitoes. The gametocytes are fertilised and
undergo further development in the mosquito, resulting in the presence of sporozoites in the mosquito
salivary glands, ready to infect another human host.
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multiplies within the human host erythrocytes
(Fig. 1). The presence of the parasite and the
resulting host inflammatory responses lead to
high fevers and associated ‘flu’-like symptoms.
In 1–2% of infections a life-threatening illness
develops, characterised by various clinical
features, including impaired consciousness,
coma, difficulty breathing, severe anaemia and
multi-organ failure (Refs 2, 3). These clinical
manifestations of severe malaria are thought to
occur because of a combination of a high
parasite burden and the sequestration of mature
P. falciparum-infected erythrocytes (IEs) in
microvascular beds throughout the body
(Ref. 4). The sequestered mass of IEs leads to
microvascular obstruction (Refs 5, 6), metabolic
disturbances, such as acidosis (Ref. 7), and
release of damaging inflammatory mediators
(Refs 8, 9), which can combine to cause severe
disease and death of the human host.
Sequestration is thought to benefit the parasite
by allowing it to avoid the host’s normal
splenic clearance mechanisms that remove aged
or damaged erythrocytes (Ref. 10).
The importance of Plasmodium
falciparum adhesion
Three major types of Plasmodium
falciparum adhesion
Sequestration occurs because parasite-derived
adhesins expressed on the surface of mature-IEs
bind to receptors on human cells. Three major
types of IE adhesion have been described
(Fig. 2): (1) cytoadherence to endothelial cells
(often referred to simply as cytoadherence or
cytoadhesion) (Ref. 11); (2) rosetting with
uninfected erythrocytes (Ref. 12); and (3)
interactions with platelets that can lead to
clumping of IEs in vitro (platelet-mediated
clumping) (Ref. 13).
An additional specialised form of adhesion
occurs during malaria in pregnancy, in which
IEs adhere to syncytiotrophoblasts to bring
about placental sequestration (Ref. 14). The
molecular mechanisms of placental
sequestration and the drive to develop a
vaccine to prevent malaria in pregnancy are
covered elsewhere (Refs 15, 16, 17) and are not
discussed here. IEs are also known to bind to a
variety of immune system cells, which has
important immunological consequences. These
immunological interactions are considered
briefly below; however, the review focuses
mainly on the first three major types of
adhesion, and considers progress in elucidating
the molecular mechanisms of adhesion and the
therapeutic implications of understanding these
important host–parasite interactions.
Which adhesion phenotypes are important
in the pathogenesis of severe malaria?
An important prerequisite for the development of
new treatments is an understanding of how
different types of adhesion contribute to
malaria pathogenesis. All P. falciparum isolates
sequester, yet not all infections lead to life-
threatening disease. So, are all types of parasite
adhesion equally damaging? Or is life-
threatening malaria linked to specific binding
phenotypes that can target IEs to vital organs
such as the brain, or cause particularly severe
microvascular obstruction? There are, as yet, no
definitive answers to these crucial questions.
However, current data suggest that there might
be geographic variation in the association
between adhesion phenotypes and severe
disease (discussed further below).
Discovering which parasite adhesion
phenotypes contribute to life-threatening
malaria has proved difficult because there is no
animal model that reflects the pathogenesis of
human malaria. Researchers have therefore
used two approaches to investigate parasite
adhesion phenotypes in relation to disease
severity. The first compares the binding
properties of field isolates derived from blood
samples of patients with different clinical forms
of malaria. Binding of IEs is assessed in static or
flow assays using purified host receptors bound
to plastic dishes, cell lines, fluorescently
labelled receptors or receptor-coated beads. The
aim of these studies is to identify parasite
adhesion phenotypes that occur at high
frequency (or show high levels of binding) in
isolates from patients with severe malaria, but
are rare (or show low levels of binding) in
isolates from patients with uncomplicated
disease. A positive correlation between a
parasite adhesion phenotype and severe disease
supports a role for that phenotype in
pathogenesis. A negative result does not,
however, prove the phenotype is unimportant,
because the assays might not adequately reflect
adhesion in vivo. A second approach has been
to use human genetic studies to investigate
whether receptor polymorphisms that reduce
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parasite adhesion confer protection against severe
malaria. The rationale for these studies is that if an
adhesion phenotype is directly involved in
causing life-threatening malaria, then any
human receptor polymorphism that reduces or
abolishes parasite adhesion should confer
protection against severe disease and death.
Examples of both types of study are given below.
Geographic variation in pathogenic
mechanisms linked tomalaria transmission
intensity and host immunity
There are distinct patterns of severe malaria in
different parts of the world linked to differences
in malaria transmission intensity. For example,
in South East Asia, where transmission is
generally low, severe malaria affects all age
Adhesion of erythrocytes infected with Plasmodium falciparum to human cells
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Figure 2. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells. (See next page for
legend.)
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groups and commonly presents as multiorgan
failure (including renal and hepatic failure,
pulmonary oedema and impaired
consciousness) (Ref. 18). Individuals suffering
from severe malaria in SE Asia usually have
had few, if any, previous malaria infections.
Conversely, in sub-Saharan Africa, transmission
levels tend to be higher and more stable, and
severe malaria is mainly a disease of children
under 5 years that presents as impaired
consciousness, severe anaemia or respiratory
distress (Ref. 2). In sub-Saharan Africa, patients
suffering from severe malaria are likely to have
had multiple previous P. falciparum infections
(Ref. 19). The distinct clinical features of severe
malaria in different parts of the world are
probably age-related, because a recent study
from a low-transmission area in Asia shows
that age has a large effect on presenting
syndromes, with seizures, respiratory distress
and anaemia being more common in children,
whereas renal and hepatic failure are more
commonly seen in adults (Ref. 3).
It remains unclear to what extent the different
levels of host immunity to malaria that occur
under different transmission intensities
influences host–parasite interactions. The
possibility that parasite phenotypes
contributing to severe disease might differ in
distinct geographical regions related to
transmission intensity has received little
attention, but is supported by recent research.
In SE Asia, a high parasite multiplication rate in
vitro and the ability of parasites to invade
erythrocytes nonselectively are linked to severe
disease (Refs 20, 21), whereas these factors are
not associated with disease severity in Africa
(Ref. 22). There is a direct link between total
parasite burden and risk of severe malaria and
death in SE Asia (Refs 23, 24), whereas the
relationship is less clear in sub-Saharan Africa,
where some children tolerate extremely high
parasitaemia without developing severe clinical
complications (Refs 2, 25). In terms of adhesion
phenotypes, rosetting is associated with severe
malaria in African children (Refs 13, 22, 26, 27,
28, 29, 30, 31, 32, 33), but is not associated with
malaria severity in SE Asia (Refs 34, 35, 36, 37).
The possible reasons why different parasite
properties are linked to severe malaria in
different regions are discussed further below. In
addition, because of the potential geographic
variation in parasite adhesion phenotypes
underlying severe malaria, we discuss studies
from areas with unstable or low transmission
(usually SE Asia) separately to studies from
areas with stable or moderate–high
transmission (sub-Saharan Africa or Papua
New Guinea).
Molecular mechanisms of P. falciparum
adhesion
In 1995, the cloning of the var genes encoding the
variant surface antigen family P. falciparum
erythrocyte membrane protein 1 (PfEMP1)
provided essential groundwork for research
into the molecular basis of adhesion in
falciparum malaria (Refs 38, 39, 40). PfEMP1
variants are expressed on the surface of IEs and
are responsible for at least some of the adhesive
Figure 2. Adhesion ofPlasmodiumfalciparum-infected erythrocytes to human cells. (Legend;Seeprevious
page for figure) (a) Schematic representation of the adhesion properties ofP. falciparum-infected erythrocytes to
different host cells. Erythrocytes infected with mature forms of P. falciparum parasites (pigmented trophozoites
and schizonts) have the ability to bind to a range of host cells, such as endothelium, uninfected erythrocytes
(rosetting) and platelets (platelet-mediated clumping). The adhesion of infected erythrocytes to endothelial
cells leads to their sequestration in the microvasculature of various organs and tissues such as heart, lung,
brain, muscle and adipose tissue. As a result, only erythrocytes carrying young ring forms of the parasite are
detected in human peripheral blood samples. Although cytoadherence and sequestration of mature infected
erythrocytes in the microvasculature occur in all infections, several specific adhesive phenotypes have been
associated with severe pathological outcomes of malaria, such as the formation of rosettes and the
adhesion of infected erythrocytes to brain endothelium. Rosetting and platelet-mediated clumping are
phenotypes that are displayed by some but not all P. falciparum isolates in vitro. In vivo, it is thought that the
formation of rosettes and clumps will be accompanied by adhesion to endothelial cells and sequestration in
the microcapillaries (Ref. 115). (b) Cytoadherence of infected erythrocytes to in-vitro-cultured brain
endothelial cells, visualised by light microscopy after Giemsa staining. (c) Rosettes detected in in vitro
P. falciparum cultures, observed after preparation of Giemsa-stained thin smears and light microscopy.
(d) Platelet-mediated clumps of infected erythrocytes formed after in vitro co-incubation of parasite cultures
with platelets, observed by Giemsa-stained thin smears and light microscopy.
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properties of IEs. Other parasite-derived variant
antigens are also present on the IE surface, such
as RIFINs (Ref. 41) and STEVORs (Ref. 42), and
have the potential to be involved in adhesion;
however, the function of these proteins remains
unknown. Var genes encode PfEMP1 variants
containing extracellular regions consisting of
tandemly arranged cysteine-rich domains called
duffy-binding-like (DBL), cysteine-rich
interdomain regions (CIDR) and C2 domains
(Ref. 43) (Fig. 3). Var genes can be divided into
three major groups (A, B and C) on the basis of
conserved upstream regions, and these
groupings have functional and clinical
significance (Refs 44, 45, 46). The role of
PfEMP1 in different types of adhesion is
Schematic representation of a parasite-derived Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1) variant on the surface of an 
infected erythrocyte
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Figure 3. Schematic representation of a parasite-derivedPlasmodiumfalciparumerythrocyte membrane
protein 1 (PfEMP1) variant on the surface of an infected erythrocyte. PfEMP1 is a family of proteins encoded
by vargenes that are transported and expressed on the surface of infected erythrocytes during the mature stages
of the intraerythrocytic cycle (pigmented trophozoite and schizont). There are approximately 60 var genes per
parasite genome, which encode 60 different variants of PfEMP1; however, only one particular variant of PfEMP1
is expressed per cell at any given time. Switching of var gene expression allows the parasite to modify the
antigenic and functional properties of infected erythrocytes, thereby evading immunity and altering adhesion
capabilities. The extracellular region of PfEMP1 has an N-terminal segment (NTS) followed by several
cysteine-rich domains known as DBL (duffy-binding-like) and CIDR (cystein-rich interdomain regions) that
can be classified into distinct types based upon sequence similarity. There are six DBL types, (a, b, g, d, 1
and X) and three CIDR types (a, b and g). The number, location and type of DBL and CIDR domains vary
among PfEMP1 variants, and this variable domain composition and extensive sequence polymorphism is
thought to provide great flexibility in binding properties. To date, the binding domains for several host
receptors, such as CD36, complement receptor 1 and ICAM1, have been mapped to individual DBL and
CIDR domains. This diagram shows a hypothetical model of a PfEMP1 variant. TM, transmembrane region.
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outlined below, and the structure, functions and
diversity of the var gene family are described in
more detail in several recent reviews (Refs 47,
48, 49). It is important to appreciate that
although each IE is thought to express only one
PfEMP1 variant at a time (out of a repertoire of
approximately 60 per parasite genome),
switching of var gene expression can occur at
each new asexual blood stage cycle, giving rise
to antigenic variation in malaria (Ref. 50). A
switch to an antigenically distinct PfEMP1
variant might result in a switch to a new
adhesion phenotype (Ref. 50). The adhesion
properties of parasite isolates are therefore not
fixed, but can change in subsequent cycles as
PfEMP1 expression changes. An individual
isolate could express a virulence-associated
adhesion phenotype, such as rosetting, in one
host, but after transmission to a new host might
express a different predominant PfEMP1
variant with a less-damaging adhesion
phenotype. The factors that determine which
var gene is selected for transcription in each IE
are currently unclear. The capacity for
phenotypic switching provides an extra level of
complexity for researchers studying parasite
adhesion properties, and studies using long-
term parasite cultures in vitro often require
regular selection procedures to maintain the
phenotype under investigation.
For each P. falciparum adhesion phenotype,
a summary is given below describing what
is known about the molecular basis of
adhesion, including information on the host
receptor, the parasite ligand and the role of the
adhesion phenotype in the pathogenesis of
severe malaria.
Molecular mechanisms of infected
erythrocyte adherence to endothelial cells
The ability of IEs to bind to microvascular
endothelial cells and become sequestered from
the peripheral blood was described in
postmortem studies of patients who died from
falciparum malaria in the 1890s (Ref. 51). Since
then, cytoadherence has received considerable
attention, and although much has been learned,
many major questions remain unanswered.
P. falciparum IEs have been shown to have the
potential for binding to a diverse array of
endothelial receptors (Table 1). Evidence for
many of these interactions is based on a single,
or small number of publications, and only
CD36 and intracellular adhesion molecule 1
(ICAM1) have been studied in detail. The
neglect of this important area is surprising, as is
the fact that it remains unclear which, if any, of
these receptors has a pivotal role in the most
life-threatening forms of malaria. Each receptor
is considered individually below; however, it is
important to remember that in vivo, multiple
receptors might combine to promote adhesion
to endothelial cells (Refs 52, 53). In particular,
receptors that promote rolling adhesion [such
as ICAM1, vascular cell adhesion molecule 1
(VCAM1) and P-selectin] might act
synergistically with static adhesion receptors
such as CD36 to enhance the overall degree of
sequestration in vivo (Refs 54, 55, 56).
CD36
IEs bind to the scavenger receptor CD36 (Refs
57, 58), which is expressed on endothelial and
epithelial cells, macrophages, monocytes,
platelets, erythrocyte precursors and adipocytes
(Ref. 59). Blocking studies using monoclonal
antibodies (Ref. 60) and peptides (Ref. 61)
suggest that the binding site for P. falciparum
involves amino acids 139-184 of CD36, although
involvement of other regions has not been
exluded.
The parasite ligands for CD36 binding are
PfEMP1 variants (Refs 38, 62) encoded by two
major subtypes of var genes (Group B and C)
(Ref. 44). The Group B and C var genes
comprise approximately 50 of the average
repertoire of 60 var genes per parasite genome
(Ref. 48). Various PfEMP1 variants have been
shown to bind CD36 via the most N-terminal
CIDR domain (Refs 63, 64, 65) (Fig. 3), and the
structure of this region has been determined
(Ref. 66).
CD36 binding is a property of almost all
P. falciparum isolates derived from malaria
patients (Ref. 30); however, the role of CD36 in
malaria pathogenesis remains uncertain
(Ref. 67). Studies in Africa have found no
difference in CD36-binding ability between
parasite isolates from severe and uncomplicated
malaria patients (Refs 30, 68, 69, 70), and
human genetic studies of CD36-deficient
malaria patients have shown conflicting (but
mostly negative) results (Table 1). On balance,
current evidence does not support a major role
for CD36 in severe malaria in sub-Saharan
Africa (Table 1).
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Table 1. Summary of known receptors for P. falciparum adhesion
Receptor Phenotype associated with
severe disease?a
Human polymorphisms
protect?a
Receptors for endothelial cell cytoadherence
CD36 Africa: No (Refs 30, 46, 68, 69, 70)
Asia: Yes (Refs 71, 72); No (Ref. 35)
Africa: No (Refs 214, 215, 216); Yes
(Ref. 217)
Asia: Yes (Ref. 73)
ICAM1 (CD54) Africa: No (Refs 30, 69, 70)
Asia: No (Refs 35, 72)
Africa: No (Refs 84, 216, 218, 219,
220); Yes (Ref. 221)
Asia: NDb
P-selectin (CD62P) ND ND
Thrombospondin Africa: No (Ref. 32)
Asia: ND
ND
PECAM1 (CD31) Africa: No (Refs 30, 32)
Asia: ND
Africa: No (Ref. 96)
Asia: No (Ref. 97)
E-selectin (CD62E) Africa: No (Ref. 30)
Asia: No (Ref. 35)
ND
VCAM1 (CD106) Africa: No (Ref. 30)
Asia: No (Ref. 35)
ND
Heparan sulphate Africa: Yes (Ref. 32)
Asia: ND
ND
Fractalkine ND ND
Integrin avb3 ND ND
Fibronectin ND ND
NCAM (CD56) ND ND
gC1qR/HABP1/p32 ND ND
Rosetting receptors on uninfected erythrocytesc
Rosetting Africa: Yes (Refs 13, 22, 26, 27, 28, 29,
30, 31, 32, 33); No (Ref. 69)
Asia: No (Refs 34, 35, 36, 37)
Complement receptor 1 ND Papua New Guinea: Yes (Ref. 127)
Africa: Yes (Ref. 223); No (Ref. 224)
Asia: No (Refs 128, 129)
A and B blood group
sugars
ND Africa: Yes (Refs 133, 134)
Asia: Yes (Ref. 135)
Heparan-sulphate-like
molecules
ND ND
Clumping receptors on plateletsc
Platelet-mediated
clumping
Africa: Yes (Refs 13, 141);
No (Ref. 142)
Asia: Yes (Ref. 37)
CD36 ND See above
gC1qR/HABP1/p32 ND ND
P-selectin ND ND
aOwing to different clinical and epidemiological features of severe malaria in regions of varying malaria
transmission, studies have been separated into ‘Africa’ and ‘Papua New Guinea’ indicating stable, moderate-
high transmission areas where severe malaria affects young children and substantial immunity develops in the
population, or ‘Asia’ indicating unstable or low transmission areas where severe malaria affects nonimmune
individuals of all age groups.
bND, not done.
cSubphenotypes of rosetting and clumping involving individual receptors have not been examined for their
relationship with disease severity.
expert reviews
http://www.expertreviews.org/ in molecular medicine
8
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
In Thailand, two small studies showed a
significant positive correlation between CD36
binding and severe malaria (Refs 71, 72), but
this was not confirmed in a third study
(Ref. 35). Only one human genetics study on
CD36 polymorphisms and malaria in SE Asia
has been reported, and this showed that CD36
deficiency protected against cerebral malaria
(Ref. 73). Therefore CD36 might have a role in
severe malaria in SE Asia, but further studies
would be valuable.
ICAM1
ICAM1 (CD54) is a member of the
immunoglobulin superfamily expressed on
endothelial cells and leukocytes. Binding of IEs
to ICAM1 causes rolling and static adhesion
(Refs 74, 75), and ICAM1 might act
synergistically with CD36 to enhance static
adhesion (Refs 53, 54). The IE-binding site on
ICAM1 has been mapped and localises to the
opposite face of ICAM1 to that used by its
natural ligand LFA-1 (Refs 76, 77, 78). The
binding sites for several distinct P. falciparum
strains were shown to be overlapping, but not
identical (Refs 76, 77, 78).
The parasite ligands for ICAM1 binding are
members of the PfEMP1 family that contain a
distinct pair of domains found only in a subset
of PfEMP1 variants (DBLb-C2 domains)
(Refs 79, 80, 81). Using a genome-wide
approach, it was shown that only some PfEMP1
variants containing the DBLb-C2 domain pair
are able to bind to ICAM1, and that the ICAM1-
binding variants are all encoded by Group B
var genes (Ref. 82).
As with CD36 binding, the
pathophysiological significance of ICAM1
binding is unclear. Field-isolate studies have
found no statistically significant association
between ICAM1 binding and severe malaria
in Africa (Refs 30, 69, 70), although increased
binding was seen in isolates from patients
with clinical malaria (severe and
uncomplicated) compared with asymptomatic
individuals (Ref. 30). An ICAM1 polymorphism
that reduces IE binding to ICAM1 under
flow conditions (Ref. 83) occurs at high
frequency in African populations (Ref. 84).
However, human genetic studies show
that this ICAM1 polymorphism does not
protect against severe malaria in sub-Saharan
Africa (Table 1), but does protect
against nonmalarial febrile illness in infants
(Ref. 85).
In Asia, ICAM1 binding is not associated with
severe malaria in field-isolate studies (Refs 35, 72),
and ICAM1 polymorphisms have not been
studied. However, histological studies have
shown that IEs and ICAM1 colocalise in the
brains of patients who died from cerebral
malaria (Ref. 86). ICAM1 is widely upregulated
on microvascular endothelial cells in the
presence of cytokines, such as tumour necrosis
factor-a (TNF-a), which reach high levels in
severe malaria (Ref. 87). Therefore it is plausible
that ICAM1-mediated cytoadherence has the
potential to contribute to sequestration
throughout the body during severe malaria.
P-selectin
P-selectin (CD62P) is a glycoprotein that
is expressed on activated platelets and
endothelial cells and is important for leukocyte
trafficking. It mediates rolling of IEs on
endothelial cells and facilitates adhesion to
CD36 in field isolates from Thailand (Refs 54,
56, 88). The parasite-binding site on P-selectin
has not been mapped, although it is known that
antibodies that inhibit interactions between
P-selectin and leukocytes do not affect
P. falciparum binding (Ref. 56).
The parasite ligand for P-selectin binding is
thought to be PfEMP1, because purified
PfEMP1 can bind to P-selectin in vitro (Ref. 89).
Specific PfEMP1 variants and binding domains
for P-selectin have not yet been identified, and
the role of P-selectin in severe malaria is
unknown (Table 1).
Thrombospondin
Thrombospondin (TSP) is an adhesive
glycoprotein released into plasma in response
to platelet activation by thrombin. It was the
first molecule identified as a receptor for
P. falciparum cytoadherence (Ref. 90), although
since then, it has received relatively little
attention. IEs bind to purified TSP in static
assays (Refs 32, 90) and bind to endothelial cells
via TSP under flow conditions (Ref. 91). IEs are
thought to bind to the Type 3 repeat regions of
TSP (Ref. 92).
The parasite ligand for TSP is controversial,
with PfEMP1 (Ref. 62), red-cell-derived
phosphatidylserine (a membrane phospholipid)
(Ref. 93) and altered Band 3 protein (Ref. 92) as
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possible candidates. No specific PfEMP1 variants
or domains have yet been shown to bind TSP.
Only one study has examined the association of
TSP binding with severe malaria, and it was
found that although most Kenyan field isolates
adhered well to TSP in a static assay, there was
no correlation with disease severity (Ref. 32).
Whether TSP polymorphisms affect adhesion of
P. falciparum or susceptibility to severe malaria
is unknown. Hence, a role for TSP binding in
severe malaria is not supported by current
evidence, but more research is needed to
confirm this.
PECAM1
Platelet endothelial cell adhesion molecule 1
(PECAM1 or CD31) is widely expressed on
endothelial cells, monocytes, platelets and
granulocytes. P. falciparum IEs from laboratory
strains (Ref. 94) and field isolates (Ref. 70) bind
to PECAM1 on endothelial cells and the
binding site has been mapped to the first four
immunoglobulin-like domains of PECAM1
(Ref. 94). The parasite ligand for PECAM1 is
thought to be PfEMP1, and both the CIDRa and
DBL2d domains of a specific PfEMP1 variant
have PECAM1-binding activity (Ref. 95).
Although approximately 50% of field isolates
from Kenya adhered well to PECAM1 in some
studies (Refs 32, 70), no significant correlation
with malaria severity was found (Refs 30, 32).
A high-frequency PECAM1 polymorphism did
not protect against severe malaria in Kenya or
Papua New Guinea (Ref. 96), whereas another
PECAM1 polymorphism increased the risk of
cerebral malaria in Thailand (Ref. 97).
E-selectin
E-selectin (CD62E) is a glycoprotein that is
expressed on endothelial cells at sites of
inflammation. Initial work with a P. falciparum
laboratory strain showed that it was possible
to select parasites for static adhesion to
E-selectin (Ref. 98). The parasite-binding site on
E-selectin has not been mapped and the
parasite ligand is unknown. Studies using
multiple Thai field isolates under flow
conditions failed to detect significant tethering,
rolling or static adhesion on E-selectin (Refs 35,
56). In African isolates, E-selectin binding was
extremely low and not associated with disease
severity (Ref. 30). The role of E-selectin in
cytoadherence is thus probably minor, if any.
VCAM1
VCAM1 (CD106) is a member of the
immunoglobulin superfamily and encodes a
cell-surface sialoglycoprotein expressed by
cytokine-activated endothelium. P. falciparum
parasites were selected in vitro for binding to
VCAM1 (Ref. 98), and field isolates from
Thailand were shown to tether and roll on
VCAM1, but static adhesion did not occur
(Refs 35, 56). In African isolates, VCAM1
binding was extremely low and not associated
with disease severity (Ref. 30). The role of
VCAM1 polymorphisms in P. falciparum
adhesion and susceptibility to severe malaria
has not been investigated.
Heparan sulphate
The glyosaminoglycan heparan sulphate has been
shown to mediate binding of rosetting IEs to
endothelial cells (Ref. 99) and heparan-
sulphate-like molecules on uninfected
erythrocytes might have a role in rosetting
(described below). It is unclear whether IE
binding to heparan sulphate on endothelial
cells can occur independently of rosetting, or
whether all parasites that bind heparan
sulphate form rosettes. Binding of heparin (a
highly sulphated form of heparan sulphate
produced by mast cells and used as a substitute
for endothelial cell heparan sulphate) has been
suggested to be dependent on N-sulphation
(Ref. 100), and requires a minimal heparin
fragment size of 10- or 12-mers (Refs 100, 101).
The parasite ligand for heparan sulphate is
PfEMP1, and the DBLa domain of a specific
PfEMP1 variant is able to bind heparin (Refs 95,
100, 102).
In a Kenyan field-isolate study, binding of
fluorescently labelled heparin was significantly
higher in isolates from patients with severe
malaria than in isolates from patients with
uncomplicated disease (Ref. 32), supporting a
role for heparan sulphate in severe malaria.
Whether there is genetic variation in the human
population affecting glycosaminoglycan
synthesis that has the potential to affect
parasite binding and malaria susceptibility is
unknown.
Other potential cytoadherence receptors
A number of other endothelial receptors for
P. falciparum cytoadherence have been
described, including fractalkine (Ref. 103),
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integrin avb3 (Ref. 104), fibronectin (Ref. 105),
NCAM (Ref. 106) and gC1qR–HABP1–p32
(Ref. 107). In all cases, the P. falciparum ligand
for these receptors is unknown and any role the
receptors have in severe malaria has not been
investigated. It is possible that clinically
important receptors for P. falciparum
cytoadherence remain to be identified.
Effects of cytoadherence on endothelial
cell function
There is mounting evidence that adhesion of IEs
to endothelium has adverse effects on endothelial
cell function. Apoptosis of endothelial cells
following interaction with IEs in vitro has been
described (Ref. 108, 109). In addition,
endothelial function measured by reactive
vasodilation following ischaemic stress is
impaired in Indonesian adults with severe
malaria (Ref. 110). This endothelial dysfunction
is linked to a low nitric oxide (NO) level (an
important regulator of endothelial cell function)
and a low plasma arginine level (the precursor
for NO formation in vivo) (Refs 110, 111). NO
has been shown to have an antiadhesive effect
on cytoadherence in vitro by preventing
upregulation of inducible cytoadherence
receptors (Ref. 112). Another possible effect of
IE cytoadherence to endothelial cells is to
induce a procoagulant state (Ref. 113); however,
the importance of coagulation in the
pathogenesis of severe malaria is currently
unknown.
Molecular mechanisms of IE rosetting
The ability of IEs to bind uninfected erythrocytes
to form rosettes (Fig. 2C) (Refs 12, 114) varies
between isolates, and high levels of rosetting
are significantly associated with severe malaria
at several sites across sub-Saharan Africa
(Table 1). However, such an association between
rosetting and severe disease is not seen in SE
Asia (Table 1).
Rosetting parasites cause enhanced
microvascular obstruction compared with
isogenic cytoadherent nonrosetting parasites
(Ref. 115), providing a plausible mechanism for
the pathological effect of rosetting. In an ex
vivo model, rosettes were disrupted by the high
shear forces in the arterial side of the
circulation, but in the postcapillary venules
the IEs adhered to the endothelium and the
uninfected erythrocytes formed rosettes on top
of the adherent cells (Ref. 115) (Fig. 2A).
Therefore, rosetting and endothelial cell
cytoadherence are intimately linked
phenotypes, and because some erythrocyte
rosetting receptors are also expressed on
endothelial cells, they might have a dual role in
endothelial cytoadherence and rosetting
(Ref. 99) (Fig. 2).
Current evidence suggests that rosetting
requires several interactions between parasite
ligands (domains of PfEMP1) and receptors on
uninfected erythrocytes. Three distinct receptors
have been identified: complement receptor 1
(CR1) (Refs 116, 117), heparan-sulphate-like
molecules (Ref. 102) and the A or B blood
group antigens (Ref. 118). CD36 (present at very
low levels on mature erythrocytes) is a receptor
for rosetting in one laboratory strain of
P. falciparum (Ref. 119), but does not seem to be
important in field isolates (Ref. 117). In
addition, the PfEMP1 variants that mediate
rosetting are predominantly of the group
A type (Refs 116, 120, 121), which do not adhere
to CD36 (Ref. 44). Serum factors such as IgM
natural antibodies might also have a role in
rosette formation (Refs 33, 122, 123, 124). One
early report that low molecular mass proteins
called ‘rosettins’ (Ref. 125) [which are probably
identical to rifins, (Ref. 41)] might be parasite
ligands for rosetting has not been confirmed.
Whether parasite proteins other than PfEMP1
are involved in rosetting is unknown.
Complement receptor 1 (CD35)
Complement receptor 1 (CR1) is a complement
regulatory protein found on erythrocytes, a
variety of leukocytes and follicular dendritic
cells (Ref. 126). The evidence that CR1 is a
rosetting receptor comes from experiments
showing that CR1-deficient erythrocytes show
greatly reduced rosetting, a monoclonal
antibody against CR1 reverses rosetting, and
soluble recombinant CR1 reverses rosetting in
both laboratory strains and field isolates
(Refs 116, 117). Rosetting IEs interact with the
C3b-binding site on CR1 (Ref. 117). The parasite
ligand for CR1-mediated rosetting is PfEMP1,
with the most N-terminal domain of PfEMP1
(DBLa) binding to normal but not CR1-deficient
red cells (Ref. 116).
Human genetic studies support a direct role for
CR1-mediated rosetting in severe malaria.
Human erythrocyte CR1 deficiency, which is
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known to reduce rosetting (Ref. 116), occurs
commonly in high malaria-transmission areas
of Papua New Guinea, and confers significant
protection against severe malaria, reducing
the risk by about two thirds (Ref. 127). In
Thailand, however, where rosetting is not
associated with severe malaria, polymorphisms
affecting erythrocyte CR1 levels might promote
susceptibility to severe disease (Refs 128, 129),
which is proposed to be due to impaired
immune complex clearance (Ref. 129). Some of
the Knops blood group polymorphisms,
which are due to single nucleotide changes in
the CR1 gene (Ref. 222), may affect malaria
susceptibility (Refs 223, 224). However,
further research is needed to examine this
possibility.
A or B blood group antigens
The A and B blood group sugars are trisaccharides
attached to a variety of erythrocyte glycoproteins
and glycolipids, and are also found on platelets,
leukocytes and endothelial cells. Every rosetting
isolate has a preference for either A or B cells,
and forms larger rosettes with erythrocytes of
the preferred blood group (Refs 118, 130, 131).
Rosetting does occur in group O cells, but the
rosettes are smaller and weaker than those
formed in A or B cells (Refs 131, 132). PfEMP1
is thought to bind to A and B sugars and a
specific variant from a rosetting parasite clone
binds to the group A trisaccharide via the
DBLa domain (Ref. 95). Human genetic studies
support a direct role for A- and B-mediated
rosetting in the pathogenesis of severe malaria,
because blood group O reduces rosetting in
field isolates (Refs 29, 133) and confers
significant protection against severe malaria
(Refs 133, 134, 135) (Table 1).
Heparan-sulphate-like molecules
These molecules on erythrocytes might act as
rosetting receptors, because rosetting is reduced
after treating red cells with an enzyme that
degrades glycoasaminoglycans (Ref. 102).
However, it is unclear whether erythrocytes
express true glycosaminoglycans, and the exact
nature of the heparan-sulphate-like molecules
on erythrocytes is not yet known (Ref. 136). It
has been shown that a specific PfEMP1 variant
can bind to heparin (Refs 95, 100, 102), and that
this interaction contributes to cytoadherence to
endothelial cells (Ref. 99). It is unclear whether
rosetting and heparan sulphate binding are
independent or identical phenotypes, and
further research is needed to fully characterise
the role of these molecules in erythrocytes and
also to determine their role in rosetting and
severe malaria.
Molecular mechanisms of P. falciparum
adhesion to platelets
P. falciparum IEs have the capacity to bind platelets
and form mixed clumps in vitro, in which platelets
act as bridges between the IEs (platelet-mediated
clumping, Fig 2D) (Ref. 13). If clumps form in
vivo, they could contribute to microvascular
obstruction. Platelets might also enhance
cytoadherence by acting as bridges between
endothelial cells and IEs and so target
sequestration to endothelial beds not expressing
adhesion receptors such as CD36 (Ref. 137).
P. falciparum interaction with platelets might
also lead to platelet activation and release
of inflammatory mediators (Ref. 138).
Accumulation of platelets has been reported in
the brains of children dying from cerebral
malaria (Ref. 139); however, the precise role of
platelets in malaria pathology remains unclear. A
recent report highlights the fact that platelets can
also have antiparasite effects in vivo, and are able
to bind to and kill IEs (Ref. 140).
Similarly to rosetting, platelet-mediated
clumping varies between parasite isolates, and
a significant association of clumping with
severe malaria has been reported from Kenya
(Ref. 13), Thailand (Ref. 37) and Malawi
(Ref. 141). However, a study in Mali found an
association with high parasitaemia, but not
severe disease (Ref. 142). The above field-isolate
studies each used different experimental
methods to assess platelet-mediated clumping,
and these different conditions have a
profound effect on the outcome of the assay
(Ref. 143). To clarify the association between
clumping and severe malaria, more field-isolate
studies will be necessary using standardised
techniques.
The molecular mechanisms of the interaction of
P. falciparum with platelets are not fully
understood; however, three platelet receptors
for clumping have been identified: CD36
(Ref. 13), globular C1q receptor (gC1qR/
HABP1/p32) (Ref. 107) and P-selectin (Ref. 141).
In all cases, the parasite ligands are unknown,
although PfEMP1 is a likely candidate molecule.
expert reviews
http://www.expertreviews.org/ in molecular medicine
12
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
CD36
CD36 is constitutively expressed on platelets, and
was shown to have a role in clumping, because
antibodies to CD36 inhibit clumping and CD36-
deficient platelets do not support clumping
(Ref. 13). However, although most parasite
isolates bind to CD36, they do not all form
clumps (Ref. 13, 50). Therefore, it seems likely
that an interaction with additional platelet
receptors or distinct epitopes on CD36 might
differentiate parasite isolates that form platelet-
mediated clumps from those that bind to CD36
but do not form clumps. As described in
Table 1, human genetic evidence does not
support an important role for CD36-mediated
adhesion in life-threatening malaria in sub-
Saharan Africa, whereas further information is
needed for Asia.
gC1qR/HABP/p32
gC1qR/HABP/p32 is a multifunctional protein
found on activated platelets and endothelial
cells, which was recently shown to act as a
receptor for clumping and endothelial cell
cytoadherence (Ref. 107). Antibodies to gC1qR/
HABP/p32 and soluble recombinant protein
inhibit clumping in some parasite isolates
(Ref. 107). The importance of this protein in
clumping of clinical isolates has not yet been
widely tested, nor is it known whether
polymorphisms that affect binding and malaria
susceptibility occur.
P-selectin
P-selectin is expressed on activated platelets and
might have an accessory role in clumping,
especially in combination with CD36 (Ref. 141);
however, this has not yet been widely tested.
There is currently very little evidence to
determine whether P-selectin binding is
important in severe malaria (Table 1).
Molecular mechanisms of IE interaction
with cells of the immune system
Many of the receptors involved in adhesion of
P. falciparum to endothelial cells, erythrocytes
and platelets are also present on subsets of
leukocytes, including CD36, ICAM1, NCAM
(CD56), gC1qR, CR1 and the A and B blood
group antigens. Therefore the potential exists
for parasites to bind to leukocytes and promote
immune cell activation and parasite clearance,
or lead to immunomodulation and immune
evasion. A consensus on whether these
interactions are beneficial or detrimental to the
human host is still lacking.
Of these immune cell receptors, CD36 is the
most well studied, yet it remains the most
controversial. Binding of IEs to macrophage
CD36 leads to phagocytosis without the
production of pro-inflammatory cytokines
(Ref. 144), suggesting that CD36 binding could
lead to parasite clearance and so favour the
host. Other evidence shows that parasite
adhesion to CD36 is implicated in the
impairment of human dendritic cell function
and subsequent inhibition of the adaptive
immune response (Refs 145, 146), and so could
favour the parasite. However, recent evidence
suggests that parasite adhesion to CD36 (or any
other receptor) is not required for the
modulation of dendritic cell function, and
instead a high dose of parasitised red blood
cells is sufficient to induce inhibition of
dendritic cell maturation (Ref. 147).
Adhesion of malaria parasites to cells of the
lymphocyte lineage has also been reported.
P. falciparum IEs form large clumps with B cells
in vitro, and a domain of PfEMP1 is sufficient
to induce B cell proliferation through an
unknown host receptor (Ref. 148). Furthermore,
a direct interaction between IEs and natural
killer cells is thought to be required for optimal
initiation of the early inflammatory cytokine
response to malaria parasites (Ref. 149). The
molecular nature of this interaction remains
unknown, although there is evidence against
the involvement of PfEMP1 binding to CD36 or
ICAM1 (Ref. 150). Indeed, PfEMP1 might
actually suppress lymphocyte IFN-g production
(Ref. 151). Interestingly, natural killer cells
express the newly identified P. falciparum
adhesion receptor NCAM (Ref. 106), although
the significance of this in malaria host–parasite
interactions is currently unknown.
Adhesion of malaria parasites to leukocytes
is complex. Many known P. falciparum receptors
with a potential immunomodulatory function
have yet to be investigated and even for
those receptors that have been studied in
detail, the physiological significance of the
interaction is largely unresolved. The potential
dual role of CD36, both in phagocytic clearance
of parasites and in immunosuppression of
dendritic cells, serves as a warning that
the therapeutic disruption of P. falciparum
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adhesion could have unintended immunological
consequences.
Clinical implications and possible
therapeutic applications
Potential for antiadhesion therapies
The discoveries outlined above illuminate some
of the adhesion interactions between
P. falciparum IEs and human cells and open up
the possibility of developing therapeutic
interventions aimed at blocking or reversing
parasite adhesion. There is good evidence that
high parasite burdens and sequestration
leading to microvascular obstruction are
important in the development of life-
threatening malaria (Refs 5, 23, 24, 51, 152, 153),
although the precise pathogenic mechanisms
leading to death and the relative contributions
of physical obstruction and metabolic
disturbances versus local release of
inflammatory mediators and vasoactive
compounds continue to be debated (Refs 6, 8, 9,
154, 155, 156). The importance of organ-specific
sequestration (e.g. the brain in cerebral malaria)
versus the total sequestered load throughout
the body, is also controversial (Ref. 157).
On the basis of current knowledge, any
therapeutic intervention able to reverse adhesion
of IEs has the potential to relieve microvascular
obstruction and could be tested as an adjunct to
standard antimalarial drugs in severely ill
malaria patients. New treatments are urgently
needed because the case mortality rate for severe
malaria is 15–20% (Ref. 158), even in well-
equipped hospitals with intensive care facilities
(Ref. 159). Standard antimalarial drugs take up to
24 hours for their parasite-killing effects to occur,
and 85% of malaria–related deaths in
hospitalised patients occur in the 24 hour period
immediately after hospital admission (Ref. 2).
The superior results obtained with artemisinine
derivatives over quinine as a first-line
antimalarial treatment in SE Asian adults with
severe malaria (Ref. 160) might be due to the
faster action of artemisinine, which acts on all
stages of parasite development, whereas quinine
only kills schizonts and mature trophozoites
(Ref. 161). Even in artemisinine-treated patients,
it is plausible that a therapy that immediately
relieves microvascular obstruction might be of
clinical benefit. It is less clear whether therapies
that are able to block further adhesion but are
unable to reverse existing adhesion would be
useful, and it seems prudent to suggest that
development of adhesion-reversing agents
should be given priority.
Adhesion-reversing therapies are likely to be
drugs, and ideally should be easy and cheap to
manufacture, have minimal side effects and
good stability (Ref. 162). Drugs that are already
in clinical use for other diseases have an
advantage in terms of development time and
costs, and some of the current candidate
antiadhesion therapies fall into this category.
Infusions of monoclonal antibodies or peptides
might also have the potential to reverse
adhesion, although it seems unlikely that such
interventions would be cheap enough to be
widely used in developing countries with
limited resources for health care. Monoclonal
antibody or peptide therapies could, however,
provide proof of principal to determine
whether adhesion-reversal is of clinical benefit,
and might be used in intensive care facilities in
more affluent countries.
Potential for antiadhesion vaccines
Knowledge of the molecular mechanisms of
parasite adhesion could be used to design
vaccines aimed at raising antibodies to block
adhesion and prevent sequestration. The spleen
would remove nonsequestered mature IEs, and
so the build-up of high parasite burdens of
avidly sequestering parasites would be avoided
and severe malaria prevented. The vaccine
approach is problematic because of the
variability of the parasite adhesion ligand
PfEMP1, although initial exploratory studies are
underway (Refs 163, 164, 165), and some
preliminary data do support the possibility that
crossreactive antibodies can be active against a
range of isolates (Refs 166, 167). Another
problem would be the logistical difficulty and
cost of testing such a vaccine, for which reduced
malaria mortality would be the primary
endpoint. Although challenging, the
development of an adhesion-blocking vaccine
would be of great value because it would have
the potential to reduce deaths from malaria
amongst the many people who currently do not
have access to treatment in well-equipped
hospitals. For this reason, even if adhesion-
reversing adjunctive therapies to be used in
hospitals can be developed, research into
adhesion-blocking vaccines should also proceed,
although the possibility that blood-stage vaccines
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could drive the evolution of parasite virulence
should be considered (Ref. 168).
Current antiadhesion drugs under
investigation
Drugs that are currently under investigation for
their potential as antiadhesion adjunctive
therapies are summarised in Table 2.
Drugs to inhibit or reverse CD36 binding
Levamisole
Levamisole is an alkaline phosphatase inhibitor
that is used as an antihelminth drug in humans.
Recent research showed that endothelial CD36
is constitutively phosphorylated and that
interaction with IEs leads to phosphatase
activity to remove the phosphate group at
Thr92 of CD36 (Refs 169, 170).
Dephosphorylated CD36 has a higher affinity
for IEs under flow conditions than
phosphorylated CD36 does, and inhibition of
phosphatase activity using levamisole leads to a
twofold reduction in IE binding in vitro
(Ref. 170). A randomised clinical trial of Thai
patients with uncomplicated malaria (12 treated
with levamisole and 9 controls) showed that
levamisole, used as an adjunctive therapy with
quinine and doxycycline, resulted in increased
numbers of early–mid trophozoites in the
peripheral blood (Ref. 171). It was suggested
that levamisole prevented the sequestration of
these parasites as they matured from ring
stages following treatment. There was no
evidence for a reversal of adhesion of existing
mature sequestered forms, and schizonts were
not seen in the peripheral blood (although it is
Table 2. Current candidate drugs for antiadhesion adjunctive therapy of severe malaria
Drug Rationale for use Other comments Clinical trials
Levamisole Blocks cytoadherence to CD36
(Refs 169, 170)
Does not reverse
adhesion
Ref. 171
N-acetylcysteine Reverses cytoadherence to CD36
(Ref. 172)
Reverses red-cell rigidity (Ref. 174)
May suppress
artemisinine action
(Ref. 177)
Ref. 176
Ref. 175
Recombinant
PfEMP1
Reverses cytoadherence to CD36
(Refs 178, 179)
NDa
(þ)Epigalloyl-
catechin-gallate
Blocks cytoadherence to ICAM1
(Ref. 180)
Does not reverse
adhesion
ND
L-arginine Reverses endothelial dysfunction
(Ref. 110)
(Refs 110, 186,
187, 188)
Fasudil Prevents apoptosis in endothelial
cells and restores endothelial
function (Ref. 189)
ND
Heparin derivatives Reverses rosetting (Refs 190, 193) Active against a subset of
parasite isolates
(Ref. 190)
ND
Curdlan sulphate Reverses rosetting (Ref. 194) Active against a broad
range of isolates
(Ref. 194)
(Ref. 196)
Soluble
complement
receptor 1
Reverses rosetting (Ref. 117) Active against a subset of
parasite isolates
(Ref. 116)
ND
aNot done.
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possible that schizonts were released but were
immediately cleared by the spleen). Further
trials are awaited to determine whether
levamisole will be of clinical benefit.
N-acetylcysteine
N-acetylcysteine (NAC) is an antioxidant drug that
is widely used in humans for the treatment of
paracetamol (acetaminophen) overdose. In vitro
studies showed that IE binding to CD36 was
reversed by 72–83% in the presence of NAC
(Ref. 172). Further rationale for the use of NAC
comes from the suggestion that NAC can reverse
the erythrocyte rigidity, which is a characteristic
feature of severe malaria (Refs 173, 174) and
might be a contributory factor to microvascular
obstruction and pathogenesis (Ref. 6). A pilot
study of NAC in Thai severe malaria patients
found that serum lactate levels (a strong
predictor of mortality in severe malaria)
normalised significantly faster in 15 patients
treated with NAC plus quinine, compared with
15 controls treated with quinine alone (Ref. 175).
Another study showed that NAC was safe for
use in Thai patients treated with artesunate
(Ref. 176). Despite these encouraging
preliminary results, a large randomised clinical
trial of NAC as an adjunctive treatment for
severe malaria, using mortality as an endpoint,
has not been reported. Indeed, a recent study
showed that NAC can interfere with the action
of artesunate during the first 6 hours of co-
incubation with P. falciparum in vitro, and
cautioned against the use of NAC as an
adjunctive treatment with artemisinine
derivatives (Ref. 177). The interaction between
the two drugs is thought to occur because the
parasitocidal effect of artemisinine takes place
via oxidative damage, which may be inhibited
by the antioxidant effect of NAC. The possibility
of antagonism between NAC and the most
effective current antimalarial drug might mean
that further tests of NAC as an adjunctive
therapy will be hard to justify.
Recombinant PfEMP1 peptide
A peptide corresponding to the minimal CD36-
binding region of PfEMP1 from the Malayan
Camp parasite strain (Refs 65, 178) has been
shown to inhibit adhesion of Thai field isolates
to an endothelial cell line in vitro under flow
conditions, and to reverse adhesion to
microvessels in vivo in a human skin graft in
SCID mice (Ref. 179). This peptide might have
potential as an adhesion-reversing therapy,
although it is unclear if it would be practical for
widescale use.
Drugs to inhibit ICAM1 binding
(1)Epigalloyl-catechin-gallate
The best example to date of the rational design of a
compound to block cytoadherence comes from
Dormeyer and co-workers (Ref. 180), who used
the crystal structure of ICAM1 to identify a
compound to block parasite binding to ICAM1
in vitro. The team used in silico screening to
identify compounds that mimicked the region
of ICAM1 that is involved in IE binding
(Ref. 76). Thirty-six candidates were identified
in an initial screen, and these were then tested
in vitro for the ability to inhibit IE adhesion to
ICAM1 under flow conditions. One compound,
(þ)epigalloyl-catechin-gallate [(þ)EGCG], was
identified that inhibited binding by 50% at
micromolar concentrations (Ref. 180). However,
this compound did not reverse adhesion. EGCG
is a naturally occurring polyphenol compound
that is a constituent of green tea and is
currently being investigated for its anticancer,
anti-inflammatory and anti-infective properties
(Refs 181, 182, 183). Substantial further work
will be required to translate these promising
preliminary findings into a useable adjunctive
therapy, and one major question that will need
to be addressed is whether the evidence for an
involvement of ICAM1 binding in severe
malaria is currently strong enough to justify the
resources required for drug development.
Whether this compound proceeds towards the
clinic or not, the study by Dormeyer and
colleagues (Ref. 180) remains an excellent
illustration of how detailed structural and
molecular information can be used for rational
drug design in malaria.
Drugs to improve endothelial cell function
L-arginine
L-arginine is the substrate for the synthesis of NO
by NO synthase. It is given intravenously and has
been used safely in humans for many years, both
in endocrine system investigations and as a
potential therapeutic agent in cardiovascular
diseases. Following on from studies in patients
showing low NO production and low plasma
arginine levels in severe malaria (Refs 184, 185),
and studies in vitro showing that NO has an
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antiadhesive effect (Ref. 112), researchers have
begun to investigate the potential for L-arginine
to be used as an adjunctive therapy for severe
malaria (Refs 186, 187, 188). They have shown
that L-arginine improves endothelial function in
adult patients with moderately severe malaria
(Ref. 110). Whether this improvement in
endothelial function will translate into clinical
benefit awaits further trials.
Fasudil
Following on from in vitro studies showing that
cytoadherence of IEs induces apoptosis of
endothelial cells via induction of the Rho kinase
pathway, it has been suggested that the Rho-
kinase inhibitor fasudil could be a useful
adjunctive therapy (Ref. 189). Fasudil reduced
P. falciparum-induced endothelial cell apoptosis
in vitro and helped restore endothelial barrier
integrity (Ref. 189). Further studies are
required to determine the pathophysiological
significance of endothelial cell apoptosis in
severe malaria, and the therapeutic potential of
fasudil.
Drugs to reverse rosetting
Sulphated glycoconjugate compounds
A variety of sulphated glycoconjugate
compounds are known to reverse P. falciparum
rosetting (Refs 190, 191, 192); however, many of
these compounds also have significant
anticoagulant properties that could cause side-
effects. A heparin derivative with reduced
anticoagulant effects has some therapeutic
potential (Ref. 193), but the rosette-disrupting
effect of heparin and its derivatives is strain-
specific (effective on about 30–50% of rosetting
isolates) (Ref. 190), which may limit its usefulness.
Another sulfated glycoconjugate that had
broader rosette-disrupting activity against a
wide range of parasite isolates is curdlan
sulphate (Ref. 194) – a drug initially developed
as an AIDS therapy (Ref. 195). Curdlan sulphate
has been shown to be safe in adult patients with
malaria in SE Asia (Ref. 196). However, this is
not the most appropriate target population for
testing the anti-rosetting effects of the drug and
it needs be tested as an adjunctive therapy for
severe malaria in African children.
Soluble CR1
Recombinant soluble CR1 (sCR1) is being
developed as a drug in humans for ischaemia-
reperfusion injuries (such as infarcts and
strokes) (Refs 197, 198) or immune-mediated
haemolysis and transfusion reactions (Ref. 199).
sCR1 disrupts rosettes in some but not all
P. falciparum rosetting isolates (Ref. 117);
therefore, it is possible that sCR1 could be of
benefit as an adjunctive therapy for severe
malaria. However, further information is
required on the ability of sCR1 to disrupt
rosettes in a broad range of clinical isolates.
Drugs to inhibit or reverse platelet binding
Owing to the involvement of platelets in
important pathological conditions such as
thrombosis and atherosclerotic vascular
diseases, there are numerous antiplatelet
therapies available for human use [e.g.
acetylsalicylic acid (aspirin), dipyridamole,
cilostazol, ticlopidin, clopidogrel, abciximab
(ReoPro), eptifibatide and tirofiban] (Refs 200,
201). The mechanisms of action of these drugs
are well understood; however, because so little
is known about the mechanisms and
consequences of interactions between
P. falciparum and platelets, it is difficult to
predict whether any of these compounds might
be beneficial in severe malaria. A recent report
suggests that some antiplatelet drugs, such as
aspirin, could actually be detrimental in
malaria, by preventing the parasite-killing
effects of platelets (Ref. 140). Further research is
needed to clarify the role of platelets in malaria
pathophysiology to take advantage of the
therapeutic options in this area.
Prospects and outstanding research
questions
Assessing which adhesion phenotypes
contribute to severe malaria
Currently, our incomplete understanding of the
adhesion mechanisms important in the most
life-threatening clinical forms of malaria is a
major obstacle to the development of adjunctive
therapies. Given the huge amount of time,
effort and money required for drug
development, only those adhesion interactions
whose involvement in severe malaria is backed
by strong scientific evidence are likely to
succeed in raising funding for drug
development and clinical trials. The logistic and
technical difficulties of carrying out field-isolate
adhesion studies might be one reason for the
neglect of this important area. For future
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studies, flow-based systems examining IE
binding to endothelial cell lines probably
provide the most physiologically relevant
approach, and allow investigation of rolling as
well as static adhesion, and synergism between
receptors that might be important in vivo (Ref. 52).
Another difficulty is the varying definition of
severe malaria used in many studies and the
choice of a suitable control group for
comparison with severe malaria patients
(Ref. 202). ‘Severe malaria’ is often considered
to be a single disease entity, whereas it is
possible that different adhesion phenotypes
contribute to distinct clinical syndromes, such
as cerebral malaria (unrousable coma),
respiratory distress (difficulty breathing) and
severe malarial anaemia (haemoglobin levels
,5 g/dl). Ideally, studies of parasite adhesion
in relation to malaria severity should use
clearly defined subtypes of severe disease,
although this could be difficult because of
overlap in syndromes in many patients, and
small numbers in some categories.
Another problem with studies of parasite
adhesion phenotypes and severe malaria is the
uncertainty as to whether the phenotype of the
parasites being tested (derived as ring stages
from peripheral blood and matured in vitro
for 12–24 hours) truly reflects the phenotype
of the sequestered mass of parasites that are
not accessible for experimentation, although
recent data suggest no substantial genetic
differences between the two populations
(Ref. 203).
Possibility of geographic variation in
parasite adhesion phenotypes causing
severe malaria
As described above, there are clear differences in
parasite phenotypes linked to severe disease in
studies from low-transmission areas such as SE
Asia (high multiplication rate and nonselective
invasion) compared with moderate–high
transmission areas such as sub-Saharan Africa
(rosetting). How might these regional
differences be explained, and could differences
in levels of host immunity be an important factor?
One consistent feature of severe malaria
throughout the world is that mortality is linked
to markers of metabolic acidosis, such as base
excess (Ref. 3) or hyperlactataemia (Ref. 204).
This metabolic acidosis is thought to result from
microvascular obstruction because of
sequestration of large numbers of IEs. We
hypothesise that in nonimmune individuals in
low-transmission areas (e.g. SE Asia), any
parasite isolate that invades red cells efficiently
and sequesters adequately can reach a high
parasite burden and cause severe disease before
the host’s immune system mounts a specific
antibody response to variant surface antigens to
remove IEs. In this case, no specific adhesion
phenotype causes severe malaria, but all
commonly observed adhesion phenotypes, such
as binding of CD36 and ICAM1, are likely to
contribute.
In sub-Saharan Africa, however, where
individuals are exposed to multiple
P. falciparum infections, parasite growth in the
human host might occur in the presence of
immune responses that reduce parasite
proliferation. In particular, initial infections in
infants might be modified by in utero exposure
to plasmodial antigens or by maternal antibody
acquired through the placenta or via breast
milk, and entirely immunologically naive
individuals in relation to Plasmodium infection
may be rare. In this case, it is possible that
only parasite isolates expressing adhesion
phenotypes that are most effective at promoting
parasite growth and survival in the face of host
immunity are able to expand rapidly enough to
reach high parasite burdens and cause severe
disease, before specific antibodies to variant
surface antigens develop. Rosetting, for
example, is associated with high parasitaemia
in vivo (Refs 205, 206), and might act either by
promoting red cell invasion (not supported by
recent evidence) (Refs 207, 208) or as an
immune-evasion mechanism that reduces
parasite clearance (R.A.C. and J.A.R.,
unpublished results). Other adhesion
phenotypes might exist that enhance parasite
survival in partially immune hosts. In this
scenario, specific adhesion phenotypes, such as
rosetting, do contribute to severe malaria.
Implications of geographic variation for
antiadhesion therapies
The above argument is speculative; however, it
does fit with existing data. If such regional
differences do exist (linked to malaria
transmission intensity and host immunity) this
has major therapeutic implications. For
example, a rosette-disrupting drug might be of
clinical benefit in sub-Saharan Africa but would
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not be an appropriate treatment for severe malaria
in SE Asia. Conversely, a drug that reverses CD36
binding might be more effective in SE Asia.
Geographical variation needs to be considered
carefully and merits further investigation to
ensure that potentially life-saving drugs are
tested on the most appropriate patient
population. Furthermore, it should not be
assumed that an antiadhesion therapy that
works in a nonimmune population will be
effective in a moderate–high transmission area,
and vice versa.
Possible problems with antiadhesion
therapies
One unanswered question in the approach of
reversing adhesion is whether the release of
large numbers of mature IEs into the circulation
could be damaging. Would the spleen be able
to cope with removing millions of IEs, or could
it lead to potentially catastrophic side effects
such as splenic rupture? In a saimiri monkey
model of falciparum malaria, immune serum
was used to reverse sequestration, without any
damaging effect to the animals, supporting the
safety of this approach (Ref. 209).
Another problem is the lack of an animal model
that truly reflects the pathophysiology of severe
falciparum malaria in humans, because it is not
currently possible to test antiadhesion therapies
in a meaningful way (none of the primate or
rodent models develop clinical and pathological
features similar to those in humans). Attempts
have been made to develop animal models of
sequestration (Refs 210, 211); however, their
relevance to human disease mechanisms is
unclear and unproven. Human vasculature
grafted onto immunodeficient mice has been
used successfully to investigate sequestration
and antiadhesion drugs (Refs 55, 179). Further
research in this area would clearly be of benefit,
and the development of humanised animal
models and transgenic parasites to enable
study of specific human: P. falciparum receptor–
ligand interactions might be one way forward
(Ref. 212).
A further potential problem with adhesion-
reversing therapies is the possibility that many
severe malaria patients might be too far down
the ‘pathogenesis pathway’ by the time they
reach hospital to derive benefit from treatment.
Reversing IE adhesion in moribund patients
could amount to shutting the stable door after
the horse has bolted. However, this cannot be
predicted in advance and only carefully
designed and adequately powered clinical trials
will provide the answer to whether adhesion-
reversing therapies can save lives.
Conclusion
Despite the above problems, the pressing need for
novel adjunctive therapies to lower the mortality
rate from severe malaria argues strongly for
further research in this area. Antiadhesion
therapies have great potential for saving lives
(Ref. 213) and further research to clarify the
adhesion phenotypes causing severe malaria
and development of interventions to reverse
adhesion should be a priority for malaria
research in the next decade.
Acknowledgements
J.A.R. and M.A. are funded by a Wellcome Trust
Senior Research Fellowship in Basic Biomedical
Science to J.A.R. (grant no. 084226) and A.C. is
funded by a Wellcome 4 year PhD studentship.
R.C. is funded by a BBSRC studentship. We are
grateful to Clare Fennell and Ash Ghumra for
reading the manuscript, and to the reviewers
for helpful comments.
References
1 Snow, R.W. et al. (2005) The global distribution of
clinical episodes of Plasmodium falciparum malaria.
Nature 434, 214-217
2 Marsh, K. et al. (1995) Indicators of life-threatening
malaria in African children. New England Journal
of Medicine 332, 1399-1404
3 Dondorp, A.M. et al. (2008) The relationship
between age and the manifestations of and
mortality associated with severe malaria. Clinical
Infectious Diseases 47, 151-157
4 Miller, L.H. et al. (2002) The pathogenic basis of
malaria. Nature 415, 673-679
5 Dondorp, A.M. et al. (2008) Direct in vivo
assessment of microcirculatory dysfunction in
severe falciparum malaria. Journal of Infectious
Diseases 197, 79-84
6 Dondorp, A.M., Pongponratn, E. and White, N.J.
(2004) Reduced microcirculatory flow in severe
falciparum malaria: pathophysiology and
electron-microscopic pathology. Acta Tropica 89,
309-317
7 Planche, T. and Krishna, S. (2006) Severe malaria:
metabolic complications. Current Molecular
Medicine 6, 141-153
expert reviews
http://www.expertreviews.org/ in molecular medicine
19
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
8 Schofield, L. (2007) Intravascular infiltrates and
organ-specific inflammation in malaria
pathogenesis. Immunology and Cell Biology 85,
130-137
9 van der Heyde, H.C. et al. (2006) A unified
hypothesis for the genesis of cerebral malaria:
sequestration, inflammation and hemostasis
leading to microcirculatory dysfunction. Trends in
Parasitology 22, 503-508
10 Mebius, R.E. and Kraal, G. (2005) Structure and
function of the spleen. Nature Reviews
Immunology 5, 606-616
11 Udeinya, I.J. et al. (1981) Falciparum malaria-
infected erythrocytes specifically bind to cultured
human endothelial cells. Science 213, 555-557
12 Udomsangpetch, R. et al. (1989) Plasmodium
falciparum-infected erythrocytes form spontaneous
erythrocyte rosettes. Journal of Experimental
Medicine 169, 1835-1840
13 Pain, A. et al. (2001) Platelet-mediated clumping of
Plasmodium falciparum-infected erythrocytes is a
common adhesive phenotype and is associated
with severe malaria. Proceedings of the National
Academy of Sciences of the United States of
America 98, 1805-1810
14 Bray, R.S. and Sinden, R.E. (1979) The sequestration
of Plasmodium falciparum infected erythrocytes in
the placenta. Transactions of the Royal Society of
Tropical Medicine and Hygiene 73, 716-719
15 Rogerson, S.J. et al. (2007) Malaria in pregnancy:
pathogenesis and immunity. Lancet Infectious
Diseases 7, 105-117
16 Duffy, P.E. and Fried, M. (2005) Malaria in the
pregnant woman. Current Topics in Microbiology
and Immunology 295, 169-200
17 Rowe, J.A. and Kyes, S.A. (2004) The role of
Plasmodium falciparum var genes in malaria in
pregnancy. Molecular Microbiology 53, 1011-1019
18 White, N.J. (1987) Clinical and pathological aspects
of severe malaria. Acta Leidensia 56, 27-47
19 Erunkulu, O.A. et al. (1992) Severe malaria in
Gambian children is not due to lack of previous
exposure to malaria. Clinical and Experimental
Immunology 89, 296-300
20 Chotivanich, K. et al. (2000) Parasite multiplication
potential and the severity of Falciparum malaria.
Journal of Infectious Diseases 181, 1206-1209
21 Simpson, J.A. et al. (1999) Red cell selectivity in
malaria: a study of multiple-infected erythrocytes.
Transactions of the Royal Society of Tropical
Medicine and Hygiene 93, 165-168
22 Deans, A.M. et al. (2006) Low multiplication rates
of African Plasmodium falciparum isolates and lack
of association of multiplication rate and red blood
cell selectivity with malaria virulence. American
Journal of Tropical Medicine and Hygiene 74,
554-563
23 Field, J.W. and Niven, J.C. (1937) A note on
prognosis in relation to parasite counts in acute
subtertian malaria. Transactions of the Royal
Society of Tropical Medicine and Hygiene 30,
569-574
24 Dondorp, A.M. et al. (2005) Estimation of the total
parasite biomass in acute falciparum malaria from
plasma PfHRP2. PLoS Medicine 2, e204
25 Lyke, K.E. et al. (2003) Association of
intraleukocytic Plasmodium falciparum malaria
pigment with disease severity, clinical
manifestations, and prognosis in severe malaria.
American Journal of Tropical Medicine and
Hygiene 69, 253-259
26 Carlson, J. et al. (1990) Human cerebral malaria:
association with erythrocyte rosetting and lack of
anti-rosetting antibodies. Lancet 336, 1457-1460
27 Treutiger, C.J. et al. (1992) Rosette formation in
Plasmodium falciparum isolates and anti-rosette
activity of sera from Gambians with cerebral or
uncomplicated malaria. American Journal of
Tropical Medicine and Hygiene 46, 503-510
28 Ringwald, P. et al. (1993) Parasite virulence factors
during falciparum malaria: rosetting,
cytoadherence, and modulation of cytoadherence
by cytokines. Infection and Immunity 61,
5198-5204
29 Rowe, A. et al. (1995) Plasmodium falciparum
rosetting is associated with malaria severity in
Kenya. Infection and Immunity 63, 2323-2326
30 Newbold, C. et al. (1997) Receptor-specific
adhesion and clinical disease in Plasmodium
falciparum. American Journal of Tropical Medicine
and Hygiene 57, 389-398
31 Kun, J.F. et al. (1998) Merozoite surface antigen
1 and 2 genotypes and rosetting of Plasmodium
falciparum in severe and mild malaria in
Lambarene, Gabon. Transactions of the Royal
Society of Tropical Medicine and Hygiene 92,
110-114
32 Heddini, A. et al. (2001) Fresh isolates from
children with severe Plasmodium falciparum
malaria bind to multiple receptors. Infection and
Immunity 69, 5849-5856
33 Rowe, J.A. et al. (2002) Nonimmune IgM, but not
IgG binds to the surface of Plasmodium falciparum-
infected erythrocytes and correlates with
rosetting and severe malaria. American Journal
of Tropical Medicine and Hygiene 66, 692-699
expert reviews
http://www.expertreviews.org/ in molecular medicine
20
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
34 Ho, M. et al. (1991) Rosette formation of
Plasmodium falciparum-infected erythrocytes from
patients with acute malaria. Infection and
Immunity 59, 2135-2139
35 Udomsangpetch, R. et al. (1996) Receptor
specificity of clinical Plasmodium falciparum
isolates: nonadherence to cell-bound E-selectin
and vascular cell adhesion molecule-1. Blood 88,
2754-2760
36 Angkasekwinai, P., Looareesuwan, S. and
Chaiyaroj, S.C. (1998) Lack of significant
association between rosette formation and
parasitized erythrocyte adherence to purified
CD36. Southeast Asian Journal of Tropical
Medicine and Public Health 29, 41-45
37 Chotivanich, K. et al. (2004) Platelet-induced
autoagglutination of Plasmodium falciparum-
infected red blood cells and disease severity in
Thailand. Journal of Infectious Diseases 189,
1052-1055
38 Baruch, D.I. et al. (1995) Cloning the P. falciparum
gene encoding PfEMP1, a malarial variant antigen
and adherence receptor on the surface of
parasitised human erythrocytes. Cell 82, 77-87
39 Smith, J.D. et al. (1995) Switches in expression of
Plasmodium falciparum var genes correlate with
changes in antigenic and cytoadherent phenotypes
of infected erythrocytes. Cell 82, 101-110
40 Su, X.-Z. et al. (1995) A large and diverse family
gene family (var) encodes 200-350 kD proteins
implicated in the antigenic variation and
cytoadherence of Plasmodium falciparum-infected
erythocytes. Cell 82, 89-99
41 Kyes, S.A. et al. (1999) Rifins: A second family of
clonally variant proteins expressed on the surface
of red cells infected with Plasmodium falciparum.
Proceedings of the National Academy of Sciences
of the United States of America 96, 9333-9338
42 Blythe, J.E. et al. (2008) Plasmodium falciparum
STEVOR proteins are highly expressed in patient
isolates and located in the surface membranes of
infected red blood cells and the apical tips of
merozoites. Infection and Immunity 76, 3329-3336
43 Smith, J.D. et al. (2000) Classification of adhesive
domains in the Plasmodium falciparum erythrocyte
membrane protein 1 family. Molecular and
Biochemical Parasitology 110, 293-310
44 Robinson, B.A., Welch, T.L. and Smith, J.D. (2003)
Widespread functional specialization of
Plasmodium falciparum erythrocyte membrane
protein 1 family members to bind CD36 analysed
across a parasite genome. Molecular Microbiology
47, 1265-1278
45 Kaestli, M. et al. (2006) Virulence of malaria is
associated with differential expression of
Plasmodium falciparum var gene subgroups in a
case-control study. Journal of Infectious Diseases
193, 1567-1574
46 Kyriacou, H.M. et al. (2006) Differential var gene
transcription in Plasmodium falciparum isolates
from patients with cerebral malaria compared to
hyperparasitaemia. Molecular and Biochemical
Parasitology 150, 211-218
47 Kyes, S.A., Kraemer, S.M. and Smith, J.D. (2007)
Antigenic Variation inPlasmodium falciparum: Gene
Organization and Regulation of the var Multigene
Family. Eukaryotic Cell 6, 1511-1520
48 Kraemer, S.M. and Smith, J.D. (2006) A family
affair: var genes, PfEMP1 binding, and malaria
disease. Current Opinion in Microbiology 9,
374-380
49 Smith, J.D. et al. (2001) Decoding the language of
vargenes and Plasmodium falciparum sequestration.
Trends in Parasitology 17, 538-545
50 Roberts, D.J. et al. (1992) Rapid switching to
multiple antigenic and adhesive phenotypes in
malaria. Nature 357, 689-692
51 Marchiafava, E. and Bignami, A. (1894) On
Summer-Autumnal Fever. The New Sydenham
Society, London.
52 Yipp, B.G. et al. (2000) Synergism of multiple
adhesion molecules in mediating cytoadherence of
Plasmodium falciparum-infected erythrocytes to
microvascular endothelial cells under flow. Blood
96, 2292-2298
53 McCormick, C.J. et al. (1997) Intercellular adhesion
molecule-1 and CD36 synergize to mediate
adherence of Plasmodium falciparum-infected
erythrocytes to cultured human microvascular
endothelial cells. Journal of Clinical Investigation
100, 2521-2529
54 Yipp, B.G. et al. (2007) Differential roles of CD36,
ICAM-1, and P-selectin in Plasmodium falciparum
cytoadherence in vivo.Microcirculation14, 593-602
55 Ho, M. et al. (2000) Visualization of Plasmodium
falciparum-endothelium interactions in human
microvasculature: mimicry of leukocyte
recruitment. Journal of Experimental Medicine
192, 1205-1211
56 Udomsangpetch, R. et al. (1997) Promiscuity of
clinical Plasmodium falciparum isolates for multiple
adhesion molecules under flow conditions. Journal
of Immunology 158, 4358-4364
57 Oquendo, P. et al. (1989) CD36 directly mediates
cytoadherence of Plasmodium falciparum
parasitized erythrocytes. Cell 58, 95-101
expert reviews
http://www.expertreviews.org/ in molecular medicine
21
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
58 Barnwell, J.W. et al. (1989) A human 88-kD
membrane glycoprotein (CD36) functions in vitro
as a receptor for a cytoadherence ligand
on Plasmodium falciparum-infected erythrocytes.
Journal of Clinical Investigation 84, 765-772
59 Greenwalt, D.E. et al. (1992) Membrane
glycoprotein CD36: a review of its roles in
adherence, signal transduction and transfusion
medicine. Blood 80, 1105-1115
60 Daviet, L. et al. (1997) Characterization of two
vaccinia CD36 recombinant-virus-generated
monoclonal antibodies (10/5, 13/10): effects on
malarial cytoadherence and platelet functions.
European Journal of Biochemistry 243, 344-349
61 Baruch, D.I. et al. (1999) CD36 peptides that block
cytoadherence define the CD36 binding region for
Plasmodium falciparum-infected erythrocytes.
Blood 94, 2121-2127
62 Baruch, D.I. et al. (1996) Plasmodium falciparum
erythocyte membrane protein 1 is a parasitised
erythrocyte receptor for adherence to CD36,
thrombospondin, and intercellular adhesion
molecule 1. Proceedings of the National Academy
of Sciences of the United States of America 93,
3497-3502
63 Miller, L.H. et al. (2002) Definition of the minimal
domain of CIDR1alpha of Plasmodium falciparum
PfEMP1 for binding CD36. Molecular and
Biochemical Parasitology 120, 321-323
64 Smith, J.D. et al. (1998) Analysis of adhesive
domains from the A4VAR Plasmodium falciparum
erythrocyte membrane protein-1 identifies a CD36
binding domain. Molecular and Biochemical
Parasitology 97, 133-148
65 Baruch, D.I. et al. (1997) Identification of a region of
PfEMP1 that mediates adherence of Plasmodium
falciparum infected erythrocytes to CD36:
conserved function with variant sequence. Blood
90, 3766-3775
66 Klein, M.M. et al. (2008) The cysteine-rich
interdomain region from the highly variable
Plasmodium falciparum erythrocyte membrane
protein-1 exhibits a conserved structure. PLoS
Pathogens 4, e1000147
67 Serghides, L. et al. (2003) CD36 and malaria:
friends or foes? Trends in Parasitology 19, 461-469
68 Marsh, K. et al. (1988) Plasmodium falciparum: the
behavior of clinical isolates in an in vitro model of
infected red blood cell sequestration. Experimental
Parasitology 65, 202-208
69 Rogerson, S.J. et al. (1999) Cytoadherence
characteristics of Plasmodium falciparum-
infected erythrocytes from Malawian children
with severe and uncomplicated malaria. American
Journal of Tropical Medicine and Hygiene 61,
467-472
70 Heddini, A. et al. (2001) Binding of Plasmodium
falciparum-infected erythrocytes to soluble platelet
endothelial cell adhesion molecule-1 (PECAM-1/
CD31): frequent recognition by clinical isolates.
American Journal of Tropical Medicine and
Hygiene 65, 47-51
71 Ho, M. et al. (1991) Clinical correlates of in vitro
Plasmodium falciparum cytoadherence. Infection
and Immunity 59, 873-878
72 Ockenhouse, C.F. et al. (1991) Molecular basis of
sequestration in severe and uncomplicated
Plasmodium falciparum malaria: differential
adhesion of infected erythrocytes to CD36 and
ICAM-1. Journal of Infection Dis 164, 163-169
73 Omi, K. et al. (2003) CD36 polymorphism is
associated with protection from cerebral
malaria. American Journal of Human Genetics
72, 364-374
74 Berendt, A.R. et al. (1989) Intercellular adhesion
molecule-1 is an endothelial cell adhesion
receptor for Plasmodium falciparum. Nature 341,
57-59
75 Chakravorty, S.J. and Craig, A. (2005) The role of
ICAM-1 in Plasmodium falciparum cytoadherence.
European Journal of Cell Biology 84, 15-27
76 Berendt, A.R. et al. (1992) The binding site on
ICAM-1 for Plasmodium falciparum-infected
erythrocytes overlaps, but is distinct from, the
LFA-1-binding site. Cell 68, 71-81
77 Ockenhouse, C.F. et al. (1992) Plasmodium
falciparum-infected erythrocytes bind ICAM-1 at a
site distinct from LFA-1, Mac-1, and human
rhinovirus. Cell 68, 63-69
78 Tse, M.T. et al. (2004) Divergent binding sites on
intercellular adhesion molecule-1 (ICAM-1) for
variant Plasmodium falciparum isolates. Molecular
Microbiology 51, 1039-1049
79 Smith, J.D. et al. (2000) Identification of a
Plasmodium falciparum intercellular adhesion
molecule-1 binding domain: a parasite adhesion
trait implicated in cerebral malaria. Proceedings of
the National Academy of Sciences of the United
States of America 97, 1766-1771
80 Chattopadhyay, R. et al. (2004) Molecular analysis
of the cytoadherence phenotype of a Plasmodium
falciparum field isolate that binds intercellular
adhesion molecule-1. Molecular and Biochemical
Parasitology 133, 255-265
81 Springer, A.L. et al. (2004) Functional
interdependence of the DBLbeta domain and c2
expert reviews
http://www.expertreviews.org/ in molecular medicine
22
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
region for binding of the Plasmodium falciparum
variant antigen to ICAM-1. Molecular and
Biochemical Parasitology 137, 55-64
82 Howell, D.P. et al. (2008) Mapping a common
interaction site used by Plasmodium falciparum
Duffy binding-like domains to bind diverse host
receptors. Molecular Microbiology 67, 78-87
83 Craig, A. et al. (2000) A functional analysis of a
natural variant of intercellular adhesion
molecule-1 (ICAM-1Kilifi). Human Molecular
Genetics 9, 525-530
84 Fernandez-Reyes, D. et al. (1997) A high frequency
African coding polymorphism in the N-terminal
domain of ICAM-1 predisposing to cerebral
malaria in Kenya. Human Molecular Genetics 6,
1357-1360
85 Jenkins, N.E. et al. (2005) A polymorphism of
intercellular adhesion molecule-1 is associated
with a reduced incidence of nonmalarial febrile
illness in Kenyan children. Clinical Infectious
Diseases 41, 1817-1819
86 Turner, G.D.H. et al. (1994) An
immunohistochemical study of the pathology of
fatal malaria. Evidence for widespread endothelial
activation and a potential role for intercellular
adhesion molecule-1 in cerebral sequestration.
American Journal of Pathology 145, 1057-1069
87 Kwiatkowski, D. et al. (1990) TNF concentration in
fatal cerebral, non-fatal cerebral, and
uncomplicated Plasmodium falciparum malaria.
Lancet 336, 1201-1204
88 Ho, M. et al. (1998) Characterization of Plasmodium
falciparum-infected erythrocyte and P-selectin
interaction under flow conditions. Blood 91,
4803-4809
89 Senczuk, A.M. et al. (2001) Plasmodium falciparum
erythrocyte membrane protein 1 functions as a
ligand for P-selectin. Blood 98, 3132-3135
90 Roberts, D.D. et al. (1985) Thrombospondin binds
falciparum malaria parasitized erythrocytes and
may mediate cytoadherence. Nature 318, 64-66
91 Rock, E.P. et al. (1988) Thrombospondin mediates
the cytoadherence of Plasmodium falciparum-
infected red cells to vascular endothelium in shear
flow conditions. Blood 71, 71-75
92 Eda, S., Lawler, J. and Sherman, I.W. (1999)
Plasmodium falciparum-infected erythrocyte
adhesion to the type 3 repeat domain of
thrombospondin-1 is mediated by a modified band
3 protein. Molecular and Biochemical Parasitology
100, 195-205
93 Eda, S. and Sherman, I.W. (2002) Cytoadherence of
malaria-infected red blood cells involves exposure
of phosphatidylserine. Cellular Physiology and
Biochemistry 12, 373-384
94 Treutiger, C.J. et al. (1997) PECAM-1/CD31, an
endothelial receptor for binding Plasmodium
falciparum-infected erythrocytes. Nature Medicine
3, 1405-1408
95 Chen, Q. et al. (2000) The semiconserved head
structure of Plasmodium falciparum erythrocyte
membrane protein 1 mediates binding to multiple
independent host receptors. Journal of
Experimental Medicine 192, 1-10
96 Casals-Pascual, C. et al. (2001) Short report: codon
125 polymorphism of CD31 and susceptibility to
malaria. American Journal of Tropical Medicine
and Hygiene 65, 736-737
97 Kikuchi, M. et al. (2001) Association of adhesion
molecule PECAM-1/CD31 polymorphism with
susceptibility to cerebral malaria in Thais.
Parasitology International 50, 235-239
98 Ockenhouse, C.F. et al. (1992) Human vascular
endothelial cell adhesion receptors for Plasmodium
falciparum-infected erythrocytes: roles for
endothelial leukocyte adhesion molecule 1 and
vascular cell adhesion molecule 1. Journal of
Experimental Medicine 176, 1183-1189
99 Vogt, A.M. et al. (2003) Heparan sulfate on
endothelial cells mediates the binding of
Plasmodium falciparum-infected erythrocytes via
the DBL1alpha domain of PfEMP1. Blood 101,
2405-2411
100 Barragan, A. et al. (2000) The duffy-binding-like
domain 1 of Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1) is a heparan sulfate
ligand that requires 12 mers for binding. Blood 95,
3594-3599
101 Skidmore, M.A. et al. (2008) Disruption of rosetting
in Plasmodium falciparum malaria with chemically
modified heparin and low molecular weight
derivatives possessing reduced anticoagulant and
other serine protease inhibition activities. Journal
of Medicinal Chemistry 51, 1453-1458
102 Chen, Q. et al. (1998) Identification of Plasmodium
falciparum erythrocyte membrane protein 1
(PfEMP1) as the rosetting ligand of the malaria
parasite P. falciparum. Journal of Experimental
Medicine 187, 15-23
103 Hatabu, T. et al. (2003) Binding of Plasmodium
falciparum-infected erythrocytes to the membrane-
bound form of Fractalkine/CX3CL1. Proceedings
of the National Academy of Sciences of the United
States of America 100, 15942-15946
104 Siano, J.P. et al. (1998) Short report: Plasmodium
falciparum: cytoadherence to alpha(v)beta3 on
expert reviews
http://www.expertreviews.org/ in molecular medicine
23
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
human microvascular endothelial cells. American
Journal of Tropical Medicine and Hygiene 59, 77-79
105 Eda, S. and Sherman, I.W. (2004) Plasmodium
falciparum-infected erythrocytes bind to the
RGD motif of fibronectin via the band
3-related adhesin. Experimental Parasitology 107,
157-162
106 Pouvelle, B. et al. (2007) Neural cell adhesion
molecule, a new cytoadhesion receptor for
Plasmodium falciparum-infected erythrocytes
capable of aggregation. Infection and Immunity 75,
3516-3522
107 Biswas, A.K. et al. (2007) Plasmodium falciparum
uses gC1qR/HABP1/p32 as a receptor to bind to
vascular endothelium and for platelet-mediated
clumping. PLoS Pathogens 3, 1271-1280
108 Pino, P. et al. (2003) Plasmodium falciparum-infected
erythrocyte adhesion induces caspase activation
and apoptosis in human endothelial cells. Journal
of Infectious Diseases 187, 1283-1290
109 Wilson, N.O. et al. (2008) Soluble factors from
Plasmodium falciparum-infected erythrocytes
induce apoptosis in human brain vascular
endothelial and neuroglia cells. Molecular and
Biochemical Parasitology 162, 172-176
110 Yeo, T.W. et al. (2007) Impaired nitric oxide
bioavailability and L-arginine reversible
endothelial dysfunction in adults with falciparum
malaria. Journal of Experimental Medicine 204,
2693-2704
111 Weinberg, J.B. et al. (2008) Arginine, nitric oxide,
carbon monoxide, and endothelial function in
severe malaria. Current Opinion in Infectious
Diseases 21, 468-475
112 Serirom, S. et al. (2003) Anti-adhesive effect of nitric
oxide on Plasmodium falciparum cytoadherence
under flow. American Journal of Pathology 162,
1651-1660
113 Francischetti, I.M. et al. (2007) Plasmodium
falciparum-infected erythrocytes induce tissue
factor expression in endothelial cells and support
the assembly of multimolecular coagulation
complexes. Journal of Thrombosis and
Haemostasis 5, 155-165
114 David, P.H. et al. (1988) Rosetting: a new
cytoadherence property of malaria-infected
erythrocytes. American Journal of Tropical
Medicine and Hygiene 38, 289-297
115 Kaul, D.K. et al. (1991) Rosetting of Plasmodium
falciparum-infected red blood cells with
uninfected red blood cells enhances microvascular
obstruction under flow conditions. Blood 78,
812-819
116 Rowe, J.A. et al. (1997) P. falciparum rosetting
mediated by a parasite-variant erythrocyte
membrane protein and complement-receptor 1.
Nature 388, 292-295
117 Rowe, J.A. et al. (2000) Mapping of the region of
complement receptor (CR) 1 required for
Plasmodium falciparum rosetting and
demonstration of the importance of CR1 in
rosetting in field isolates. Journal of Immunology
165, 6341-6346
118 Carlson, J. and Wahlgren, M. (1992) Plasmodium
falciparum erythrocyte rosetting is mediated by
promiscuous lectin-like interactions. Journal of
Experimental Medicine 176, 1311-1317
119 Handunnetti, S.M. et al. (1992) Involvement of
CD36 on erythrocytes as a rosetting receptor for
Plasmodium falciparum-infected erythrocytes.
Blood 80, 2097-2104
120 Russell, C. et al. (2005) Further definition of
PfEMP-1 DBL-1alpha domains mediating
rosetting adhesion of Plasmodium falciparum.
Molecular and Biochemical Parasitology 144,
109-113
121 Vigan-Womas, I. et al. (2008) An in vivo and in vitro
model of Plasmodium falciparum rosetting and
autoagglutination mediated by varO, a group A
var gene encoding a frequent serotype. Infection
and Immunity 76, 5565-5580
122 Scholander, C. et al. (1996) Novel fibrillar structure
confers adhesive property to malaria-infected
erythrocytes. Nature Medicine 2, 204-208
123 Treutiger, C.J. et al. (1999) Rouleaux-forming
serum proteins are involved in the rosetting of
Plasmodium falciparum-infected erythrocytes.
Experimental Parasitology 93, 215-224
124 Ghumra, A. et al. (2008) Identification of residues
in the Cmu4 domain of polymeric IgM essential for
interaction with Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1). Journal of
Immunology 181, 1988-2000
125 Helmby, H. et al. (1993) Rosetting Plasmodium
falciparum-infected erythrocytes express unique
strain-specific antigens on their surface. Infection
and Immunity 61, 284-288
126 Khera, R. and Das, N. (2009) Complement Receptor
1: Disease associations and therapeutic
implications. Molecular Immunology 46, 761-772
127 Cockburn, I.A. et al. (2004) A human complement
receptor 1 polymorphism that reduces Plasmodium
falciparum rosetting confers protection against
severe malaria. Proceedings of the National
Academy of Sciences of the United States of
America 101, 272-277
expert reviews
http://www.expertreviews.org/ in molecular medicine
24
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
128 Nagayasu, E. et al. (2001) CR1 density
polymorphism on erythrocytes of falciparum
malaria patients in Thailand. American Journal of
Tropical Medicine and Hygiene 64, 1-5
129 Teeranaipong, P. et al. (2008) A functional single-
nucleotide polymorphism in the CR1 promoter
region contributes to protection against cerebral
malaria. Journal of Infectious Diseases 198,
1880-1891
130 Udomsangpetch, R. et al. (1993) The effects of
hemoglobin genotype and ABO blood group on
the formation of rosettes by Plasmodium falciparum-
infected red blood cells. American Journal of
Tropical Medicine and Hygiene 48, 149-153
131 Barragan, A. et al. (2000) Blood group A antigen is a
coreceptor in Plasmodium falciparum rosetting.
Infection and Immunity 68, 2971-2975
132 Carlson, J. et al. (1994) Natural protection against
severe Plasmodium falciparum malaria due to
impaired rosette formation. Blood 84, 3909-3914
133 Rowe, J.A. et al. (2007) Blood group O protects
against severe Plasmodium falciparum malaria
through the mechanism of reduced rosetting.
Proceedings of the National Academy of Sciences
of the United States of America 104, 17471-17476
134 Fry, A.E. et al. (2008) Common variation in the ABO
glycosyltransferase is associated with
susceptibility to severe Plasmodium falciparum
malaria. Human Molecular Genetics 17, 567-576
135 Pathirana, S.L. et al. (2005) ABO-blood-group types
and protection against severe, Plasmodium
falciparum malaria. Annals of Tropical Medicine
and Parasitology 99, 119-124
136 Vogt, A.M. et al. (2004) Heparan sulphate
identified on human erythrocytes: a Plasmodium
falciparum receptor. Biochemical Journal 381,
593-597
137 Wassmer, S.C. et al. (2004) Platelets reorient
Plasmodium falciparum-infected erythrocyte
cytoadhesion to activated endothelial cells. Journal
of Infectious Diseases 189, 180-189
138 Srivastava, K. et al. (2008) Platelet factor 4 mediates
inflammation in experimental cerebral malaria.
Cell Host and Microbe 4, 179-187
139 Grau, G.E. et al. (2003) Platelet accumulation in
brain microvessels in fatal pediatric cerebral
malaria. Journal of Infectious Diseases 187, 461-466
140 McMorran, B.J. et al. (2009) Platelets kill
intraerythrocytic malarial parasites and mediate
survival to infection. Science 323, 797-800
141 Wassmer, S.C. et al. (2008) Platelet-induced
clumping of Plasmodium falciparum-infected
erythrocytes from Malawian patients with cerebral
malaria-possible modulation in vivo by
thrombocytopenia. Journal of Infectious Diseases
197, 72-78
142 Arman, M. et al. (2007) Platelet-mediated
clumping of Plasmodium falciparum infected
erythrocytes is associated with high parasitemia
but not severe clinical manifestations of malaria in
African children. American Journal of Tropical
Medicine and Hygiene 77, 943-946
143 Arman, M. and Rowe, J.A. (2008) Experimental
conditions affect the outcome of Plasmodium
falciparum platelet-mediated clumping assays.
Malaria Journal 7, 243
144 McGilvray, I.D. et al. (2000) Nonopsonic
monocyte/macrophage phagocytosis of
Plasmodium falciparum-parasitized erythrocytes: a
role for CD36 in malarial clearance. Blood 96,
3231-3240
145 Urban, B.C. et al. (1999) Plasmodium falciparum-
infected erythrocytes modulate the maturation of
dendritic cells. Nature 400, 73-77
146 Urban, B.C., Willcox, N. and Roberts, D.J. (2001) A
role for CD36 in the regulation of dendritic cell
function. Proceedings of the National Academy of
Sciences of the United States of America 98,
8750-8755
147 Elliott, S.R. et al. (2007) Inhibition of dendritic cell
maturation by malaria is dose dependent and does
not require Plasmodium falciparum erythrocyte
membrane protein 1. Infection and Immunity 75,
3621-3632
148 Donati, D. et al. (2004) Identification of a polyclonal
B-cell activator in Plasmodium falciparum. Infection
and Immunity 72, 5412-5418
149 Artavanis-Tsakonas, K. et al. (2003) Activation of a
subset of human NK cells upon contact with
Plasmodium falciparum-infected erythrocytes.
Journal of Immunology 171, 5396-5405
150 Baratin, M. et al. (2007) Dissection of the role of
PfEMP1 and ICAM-1 in the sensing of Plasmodium
falciparum-infected erythrocytes by natural killer
cells. PLoS ONE 2, e228
151 D’Ombrain, M.C. et al. (2007) Plasmodium
falciparum erythrocyte membrane protein-1
specifically suppresses early production of host
interferon-gamma. Cell Host and Microbe 2,
130-138
152 MacPherson, G.G. et al. (1985) Human cerebral
malaria. A quantitative ultrastructural analysis of
parasitized erythrocyte sequestration. American
Journal of Pathology 119, 385-401
153 Taylor, T.E. et al. (2004) Differentiating the
pathologies of cerebral malaria by
expert reviews
http://www.expertreviews.org/ in molecular medicine
25
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
postmortem parasite counts. Nature Medicine 10,
143-145
154 Dondorp, A.M. (2008) Clinical significance of
sequestration in adults with severe malaria.
Transfusion Clinique et Biologique 15, 56-57
155 Artavanis-Tsakonas, K., Tongren, J.E. and Riley,
E.M. (2003) The war between the malaria parasite
and the immune system: immunity,
immunoregulation and immunopathology.
Clinical and Experimental Immunology 133,
145-152
156 Francischetti, I.M. (2008) Does activation of the
blood coagulation cascade have a role in malaria
pathogenesis? Trends in Parasitology 24, 258-263
157 Seydel, K.B. et al. (2006) The distribution and
intensity of parasite sequestration in comatose
Malawian children. Journal of Infectious Diseases
194, 208–205
158 WHO (2000) Severe falciparum malaria. World
Health Organization, Communicable Diseases
Cluster. Transactions of the Royal Society of
Tropical Medicine and Hygiene 94 Suppl 1, S1-90
159 Bruneel, F. et al. (2003) The clinical spectrum of
severe imported falciparum malaria in the
intensive care unit: report of 188 cases in adults.
American Journal of Respiratory and Critical Care
Medicine 167, 684-689
160 Dondorp, A. et al. (2005) Artesunate versus
quinine for treatment of severe falciparum malaria:
a randomised trial. Lancet 366, 717-725
161 Skinner, T.S. et al. (1996) In vitro stage-specific
sensitivity of Plasmodium falciparum to quinine and
artemisinin drugs. International Journal for
Parasitology 26, 519-525
162 Wang, C.C. (1997) Validating targets for
antiparasite chemotherapy. Parasitology 114
Suppl, S31-44
163 Duffy, P.E., Craig, A.G. and Baruch, D.I. (2001)
Variant proteins on the surface of malaria-infected
erythrocytes–developing vaccines. Trends in
Parasitology 17, 354-356
164 Baruch, D.I. et al. (2002) Immunization of Aotus
monkeys with a functional domain of the
Plasmodium falciparum variant antigen induces
protection against a lethal parasite line.
Proceedings of the National Academy of
Sciences of the United States of America 99,
3860-3865
165 Chen, Q. et al. (2004) Immunization with PfEMP1-
DBL1alpha generates antibodies that disrupt
rosettes and protect against the sequestration of
Plasmodium falciparum-infected erythrocytes.
Vaccine 22, 2701-2712
166 Gamain, B., Miller, L.H. and Baruch, D.I. (2001) The
surface variant antigens of Plasmodium falciparum
contain cross-reactive epitopes. Proceedings of the
National Academy of Sciences of the United States
of America 98, 2664-2669
167 Baruch, D.I., Gamain, B. and Miller, L.H. (2003)
DNA immunization with the cysteine-rich
interdomain region 1 of the Plasmodium falciparum
variant antigen elicits limited cross-reactive
antibody responses. Infection and Immunity 71,
4536-4543
168 Gandon, S. et al. (2003) Imperfect vaccination:
some epidemiological and evolutionary
consequences. Proceedings of the Royal Society B
Biological Sciences 270, 1129-1136
169 Yipp, B.G. et al. (2003) Src-family kinase
signaling modulates the adhesion of Plasmodium
falciparum on human microvascular endothelium
under flow. Blood 101, 2850-2857
170 Ho, M. et al. (2005) Ectophosphorylation of CD36
regulates cytoadherence of Plasmodium falciparum
to microvascular endothelium under flow
conditions. Infection and Immunity 73, 8179-8187
171 Dondorp, A.M. et al. (2007) Levamisole inhibits
sequestration of infected red blood cells in patients
with falciparum malaria. Journal of Infectious
Diseases 196, 460-466
172 Gruarin, P. et al. (2001) Cytoadherence of
Plasmodium falciparum-infected erythrocytes is
mediated by a redox-dependent conformational
fraction of CD36. Journal of Immunology 167,
6510-6517
173 Dondorp, A.M. et al. (1997) Prognostic
significance of reduced red blood cell
deformability in severe falciparum malaria.
American Journal of Tropical Medicine and
Hygiene 57, 507-511
174 Nuchsongsin, F. et al. (2007) Effects of malaria
heme products on red blood cell deformability.
American Journal of Tropical Medicine and
Hygiene 77, 617-622
175 Watt, G., Jongsakul, K. and Ruangvirayuth, R.
(2002) A pilot study of N-acetylcysteine as
adjunctive therapy for severe malaria. Quarterly
Journal of Medicine 95, 285-290
176 Treeprasertsuk, S. et al. (2003) N-acetylcysteine in
severe falciparum malaria in Thailand. Southeast
Asian Journal of Tropical Medicine and Public
Health 34, 37-42
177 Arreesrisom, P. et al. (2007) Suppressive effects
of the anti-oxidant N-acetylcysteine on the
anti-malarial activity of artesunate. Parasitology
International 56, 221-226
expert reviews
http://www.expertreviews.org/ in molecular medicine
26
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
178 Cooke, B.M. et al. (1998) A recombinant
peptide based on PfEMP-1 blocks and reverses
adhesion of malaria-infected red blood cells
to CD36 under flow. Molecular Microbiology
30, 83-90
179 Yipp, B.G. et al. (2003) Recombinant PfEMP1
peptide inhibits and reverses cytoadherence of
clinical Plasmodium falciparum isolates in vivo.
Blood 101, 331-337
180 Dormeyer, M. et al. (2006) Rational design of
anticytoadherence inhibitors for Plasmodium
falciparum based on the crystal structure of human
intercellular adhesion molecule 1. Antimicrobial
Agents and Chemotherapy 50, 724-730
181 Benelli, R. et al. (2002) Anti-invasive effects
of green tea polyphenol epigallocatechin-
3-gallate (EGCG), a natural inhibitor of metallo
and serine proteases. Biological Chemistry 383,
101-105
182 Fassina, G. et al. (2004) Mechanisms of inhibition of
tumor angiogenesis and vascular tumor growth by
epigallocatechin-3-gallate. Clinical Cancer
Research 10, 4865-4873
183 Yoda, Y. et al. (2004) Different susceptibilities of
Staphylococcus and Gram-negative rods to
epigallocatechin gallate. Journal of Infection and
Chemotherapy 10, 55-58
184 Anstey, N.M. et al. (1996) Nitric oxide in Tanzanian
children with malaria: inverse relationship
between malaria severity and nitric oxide
production/nitric oxide synthase type 2
expression. Journal of Experimental Medicine 184,
557-567
185 Lopansri, B.K. et al. (2003) Low plasma arginine
concentrations in children with cerebral malaria
and decreased nitric oxide production. Lancet 361,
676-678
186 Yeo, T.W. et al. (2008) Pharmacokinetics of
L-arginine in adults with moderately severe
malaria. Antimicrobial Agents and Chemotherapy
52, 4381-4387
187 Yeo, T.W. et al. (2008) Recovery of endothelial
function in severe falciparum malaria: relationship
with improvement in plasma L-arginine and blood
lactate concentrations. Journal of Infectious
Diseases 198, 602-608
188 Yeo, T.W. et al. (2008) Safety profile of L-arginine
infusion in moderately severe falciparum
malaria. PLoS ONE 3, e2347
189 Taoufiq, Z. et al. (2008) Rho kinase inhibition in
severe malaria: thwarting parasite-induced
collateral damage to endothelia. Journal of
Infectious Diseases 197, 1062-1073
190 Carlson, J. et al. (1992) Disruption of Plasmodium
falciparum erythrocyte rosettes by standard heparin
and heparin devoid of anticoagulant activity.
American Journal of Tropical Medicine and
Hygiene 46, 595-602
191 Rowe, A. et al. (1994) Plasmodium falciparum: a
family of sulphated glycoconjugates disrupts
erythrocyte rosettes. Experimental Parasitology 79,
506-516
192 Rogerson, S.J. et al. (1994) Sulfated glycoconjugates
as disrupters of Plasmodium falciparum erythrocyte
rosettes. American Journal of Tropical Medicine
and Hygiene 51, 198-203
193 Vogt, A.M. et al. (2006) Release of sequestered
malaria parasites upon injection of a
glycosaminoglycan. PLoS Pathogens 2, e100
194 Kyriacou, H.M. et al. (2007) In vitro inhibition of
Plasmodium falciparum rosette formation by
Curdlan sulfate. Antimicrobial Agents and
Chemotherapy 51, 1321-1326
195 Kaneko, Y. et al. (1990) Inhibition of HIV-1
infectivity with curdlan sulfate in vitro.
Biochemical Pharmacology 39, 793-797
196 Havlik, I. et al. (2005) Curdlan sulphate in human
severe/cerebral Plasmodium falciparum malaria.
Transactions of the Royal Society of Tropical
Medicine and Hygiene 99, 333-340
197 Weisman, H.F. et al. (1990) Soluble human
complement receptor type I: In vivo inhibitor of
complement suppressing post-ischaemic
myocardial inflammation and necrosis. Science
249, 146-151
198 Keshavjee, S. et al. (2005) A randomized, placebo-
controlled trial of complement inhibition in
ischemia-reperfusion injury after lung
transplantation in human beings. Journal of
Thoracic and Cardiovascular Surgery 129, 423-428
199 Yazdanbakhsh, K. (2005) Review: complement
receptor 1 therapeutics for prevention of
immune hemolysis. Immunohematology
21, 109-118
200 Ahrens, I., Bode, C. and Peter, K. (2005) Inhibition
of platelet activation and aggregation. Handbook
of Experimental Pharmacology 443-462
201 Bennett, J.S. (2001) Novel platelet inhibitors.
Annual Review of Medicine 52, 161-184
202 Nacher, M. et al. (2001) Case-control studies on host
factors in severe malaria. Trends in Parasitology 17,
253-254
203 Montgomery, J. et al. (2006) Genetic Analysis
of Circulating and Sequestered Populations
of Plasmodium falciparum in Fatal Pediatric
Malaria. Journal of Infectious Diseases 194, 115-122
expert reviews
http://www.expertreviews.org/ in molecular medicine
27
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
204 Krishna, S. et al. (1994) Lactic acidosis and
hypoglycaemia in children with severe malaria:
pathophysiological and prognostic significance.
Transactions of the Royal Society of Tropical
Medicine and Hygiene 88, 67-73
205 Rowe, J.A. et al. (2002) Positive correlation between
rosetting and parasitemia in Plasmodium falciparum
clinical isolates. American Journal of Tropical
Medicine and Hygiene 66, 458-460
206 Le Scanf, C. et al. (2008) Rosetting is associated with
increased Plasmodium falciparum in vivo
multiplication rate in the Saimiri sciureus monkey.
Microbes and Infection 10, 447-451
207 Clough, B., Atilola, F.A. and Pasvol, G. (1998) The
role of rosetting in the multiplication ofPlasmodium
falciparum: rosette formation neither enhances nor
targets parasite invasion into uninfected
red cells. British Journal of Haematology 100,
99-104
208 Deans, A.M. and Rowe, J.A. (2006) Plasmodium
falciparum: Rosettes do not protect merozoites from
invasion-inhibitory antibodies. Experimental
Parasitology 112, 269-273
209 David, P.H. et al. (1983) Parasite sequestration in
Plasmodium falciparum malaria: spleen and
antibody modulation of cytoadherence of infected
erythrocytes. Proceedings of the National
Acadamy of Science of the United States of
America 80, 5075-5079
210 Willimann, K. et al. (1995) In vivo sequestration of
Plasmodium falciparum-infected human
erythrocytes: a severe combined
immunodeficiency mouse model for cerebral
malaria. Journal of Experimental Medicine 182,
643-653
211 Pettersson, F. et al. (2005) Whole-body imaging of
sequestration of Plasmodium falciparum in the rat.
Infection and Immunity 73, 7736-7746
212 McIntosh, R.S. et al. (2007) The importance of
human FcgammaRI in mediating protection to
malaria. PLoS Pathogens 3, e72
213 Simmons, D.L. (2005) Anti-adhesion
therapies. Current Opinion in Pharmacology 5,
398-404
214 Aitman, T.J. et al. (2000) Malaria susceptibility and
CD36 mutation. Nature 405, 1015-1016
215 Ayodo, G. et al. (2007) Combining evidence of
natural selection with association analysis
increases power to detect malaria-resistance
variants. American Journal of Human Genetics 81,
234-242
216 Amodu, O.K. et al. (2005) Plasmodium falciparum
malaria in south-west Nigerian children: is the
polymorphism of ICAM-1 and E-selectin genes
contributing to the clinical severity of malaria?
Acta Tropica 95, 248-255
217 Pain, A. et al. (2001) A non-sense mutation in Cd36
gene is associated with protection from severe
malaria. Lancet 357, 1502-1503
218 Bellamy, R., Kwiatkowski, D. and Hill, A.V. (1998)
Absence of an association between intercellular
adhesion molecule 1, complement receptor 1 and
interleukin 1 receptor antagonist gene
polymorphisms and severe malaria in a West
African population. Transactions of the Royal
Society of Tropical Medicine and Hygiene 92,
312-316
219 Ndiaye, R. et al. (2005) Genetic study of ICAM1 in
clinical malaria in Senegal. Tissue Antigens 65,
474-480
220 Fry, A.E. et al. (2008) Variation in the ICAM1
gene is not associated with severe malaria
phenotypes. Genes and Immunity 9, 462-469
221 Kun, J.F. et al. (1999) Association of the
ICAM-1Kilifi mutation with protection against
severe malaria in Lambarene, Gabon. American
Journal of Tropical Medicine and Hygiene 61,
776-779
222 Moulds, J.M. et al. (2001) Molecular identification
of Knops blood group polymorphisms found in
long homologous region D of complement receptor
1. Blood 97, 2879-2885
223 Thathy, V. et al. (2005) Complement receptor 1
polymorphisms associated with resistance to
severe malaria in Kenya. Malaria Journal 4, 54
224 Zimmerman, P.A. et al. (2003) CR1 Knops blood
group alleles are not associated with severe malaria
in the Gambia. Genes and Immunity 4, 368-373
expert reviews
http://www.expertreviews.org/ in molecular medicine
28
Accession information: doi:10.1017/S1462399409001082; Vol. 11; e16; May 2009
&2009 Cambridge University Press
A
d
he
si
o
n
o
f
P
la
sm
od
iu
m
fa
lc
ip
ar
u
m
-i
nf
ec
te
d
er
yt
hr
o
cy
te
s
to
hu
m
an
ce
lls
:
m
o
le
cu
la
r
m
ec
ha
ni
sm
s
an
d
th
er
ap
eu
ti
c
im
p
lic
at
io
ns
Further reading, resources and contacts
Books
Warrell, D.A. and Gilles, H.M. eds (2002) Essential Malariology, 4th Edition, Oxford University Press.
This book provides a broad background to malariology.
Sherman, I.W. ed. (2005) Molecular Approaches to Malaria, ASM Press.
A good overview of current molecular approaches to malaria research.
Websites
For up-to-date information on malaria risks, epidemiology and prevention see:
http://www.cdc.gov/Malaria/
For general information on malaria:
http://www.who.int/topics/malaria/en/
For information on malaria parasite biology, biochemistry and physiology see:
http://sites.huji.ac.il/malaria/
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Figures
Figure 1. Life cycle of Plasmodium falciparum.
Figure 2. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells.
Figure 3. Schematic representation of a parasite-derived Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1) variant on the surface of an infected erythrocyte.
Tables
Table 1. Summary of known receptors for P. falciparum adhesion.
Table 2. Current candidate drugs for antiadhesion adjunctive therapy of severe malaria.
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